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ABSTRACT
Cul3-based E3 ligase is responsible for regulating a variety of cellular
pathways, many of which are known to have profound effects on the proper
function of multicellular organisms. Although progress over the past years has
been truly impressive, our understanding of the mechanisms of E2 recruitment and
selection by the BCR complex and all the roles that Cul3 plays on kidneys remains
in its infancy. To explore these aspects, this dissertation aims to analyze the Cul3
complex using two different approaches: (1) We used the powerful tool of chimeric
analysis to map the essential domain binding characteristics of Cul3 taking
advantage of the fact that the well-characterized cullin family members exist with
non-redundant functions. We hypothesized that besides the substrate recruitment
role, Cul3 substrate selection subunits must also be involved in E2 selection since
the E2 is responsible for determining the branching pattern of ubiquitin. From this
analysis, we characterized a unique role for the substrate adaptor subunits. (2) We
performed a quantitative proteomics analysis utilizing a newly created kidney cell
line with Cul3 deleted to identify potential new degradation substrates in kidneys.
We hypothesized that the phenotypic difference between Cul3 knockouts in
kidneys and known Cul3 substrate knockouts in kidneys imply other important
substrates exist. This analysis identified both known substrates, validating the
study, and new and novel substrates that remain to be characterized.
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GLOSSARY
BTB: A domain found in proteins that function as Cul3 substrate adaptors. The
BTB domain binds to Cul3.
Cre: Cre recombinase is an enzyme that can be used in a conditional knockout
mouse model to recombine the DNA that is surrounded by two LoxP sites (floxed).
Ctb73: A putative substrate adaptor for Cul3, Ctb73 contains an N-terminus BTB
domain, a central BACK domain, and a C-terminus PHR domain.
Cullin-based E3 ligases: They are multi-subunit E3 ubiquitin ligases which use a
specific cullin as a central scaffold. All the cullin complexes use their C-terminus
to recruit a RING-Box protein (Rbx1 or Rbx2), required for the interaction with an
E2, and their N-terminus to interact with the substrate adaptor subunit.
Cul1: One of two E3 ligases responsible for cyclin E ubiquitination. Cul1 uses
substrate adaptors with two subunits: The Skp1 linker protein and an F-box protein.
Cul3 Δ403-459: A Cul3 mutation that results in the skipping of exon 9 of the Cul3
protein. This mutation causes FHHt in humans.
Cul3: An E3 ubiquitin ligase that targets many substrates, including cyclin E, for
ubiquitination. Cul3 uses BTB-domain containing proteins as substrate adaptors.
Cul3Δ51-67: This Cul3 mutant lacks the region near its N-terminus that is
responsible for binding BTB proteins (substrate adaptors).
Cyclin E: Cyclin E controls the G1/S transition in the cell cycle by binding and
activating Cdk2. Cyclin E/Cdk2 complexes phosphorylate themselves in addition
to many other substrates including the Rb protein. Eukaryotes contain two cyclin
E proteins, cyclin E1 and cyclin E2, which are products of two different genes.

xv

E1 ubiquitin activating enzyme: E1 enzymes are responsible for activating the
C-terminus Gly-Gly motif on ubiquitin and preparing it for attachment to a
substrate. Activation of ubiquitin by an E1 occurs via an ATP-dependent reaction.
E2 ubiquitin conjugating enzyme: E2 enzymes work with E3 ubiquitin ligases in
order to transfer ubiquitin to substrates.
E3 ubiquitin ligase: E3 ligases provide substrate specificity to the ubiquitin
system. Cullin E3s work with an E2 to facilitate ubiquitin attachment. HECT E3
ligases and cullin ligases represent two classes of E3s.
F-box: Cul1 utilizes substrate adaptors, such as Fbxw7, that contain F-box
domains to recognize substrates.
FAZF: A BTB protein that also contains a zinc-finger domain. FAZF binds LRR5
(FMOD)
Fbxw7: An F-box protein that functions as a substrate adaptor for Cul1. Fbxw7 is
involved in Cul1-mediated ubiquitination of cyclin E. xiii
Keap1: A prominent member of the BTB-BACK-Kelch family of proteins, Keap1
targets the transcription factor Nrf2 for degradation.
Kelch domain: A common substrate-recognition domain that is found in many
BTB domain-containing proteins. Some notable members of this family are Keap1,
which regulates Nrf2, and Klhl3, which is involved in blood pressure regulation.
Klhl3: A BTB-BACK-Kelch protein that has been shown to cause FHHt in humans
when mutated.
MATH domain: A secondary domain that is found in the Cul3 substrate adaptor
SPOP.

xvi

MG132: A proteasome inhibitor that when added to cultured cells, results in
increased stability of some ubiquitin-proteasome system substrates.
Nedd8: Nedd8 is a ubiquitin-like molecule involved in Cul3 function. Cul3 is
modified by Nedd8 on K712.
Nrf2: Nrf2 is a transcription factor involved in the stress-response. Nrf2 is a
substrate of the Keap1 BTB-Kelch protein and Cul3.
PLZF: A zinc-finger domain containing BTB protein. PLZF is closely related to
FAZF.
Rb: The retinoblastoma protein plays a crucial role in cell cycle progression, as it
is responsible for binding and sequestering the E2 factor (E2F) family of
transcription factors, which are believed to play a crucial role in cell division control.
Sufficient phosphorylation of Rb by cyclin/Cdk pairs results in the release of E2F,
allowing for transcription of S- phase associated genes to begin.
Rbx1: The “ring-finger” protein, which interacts with cullin ubiquitin E3 ligases near
their C-termini. Rbx1 is believed to play a role in E2 binding.
RhoA: RhoA is a small GTPase that regulates many processes, including the actin
cytoskeleton.
RhoBTB3: A member of the RhoBTB protein family that binds cyclin E.
Skp1: Skp1 forms part of Cul1-based complexes as it is responsible for linking
Cul1 with an F-box protein.
SPOP: Also called Ctb75, SPOP is a Cul3 substrate adaptor (BTB protein).
Substrate adaptor subunit: Substrate adaptors are proteins that bind to cullinbased E3 ligases in order to recognize specific substrates for ubiquitination. Each
xvii

cullin ligase can associate with many different substrate adaptors, allowing each
cullin to have many substrates.
UbE2E1: UbE2E1 is an E2 ubiquitin conjugating enzyme, which forms degradative
(K48) ubiquitin linkages. UbE2E1 binds RhoBTB3.
Ubiquitin: Ubiquitin is a small protein that gets attached to target proteins, often
resulting in their degradation.
WNK1: With no lysine (K) 1: A kinase involved in NCC regulation. WNK1 can bind
and be ubiquitinated by Klhl3.
WNK4: With no lysine (K) 4: A kinase involved in NCC regulation. WNK4 interacts
with and can be ubiquitinated by Klhl3.
Zinc Finger domain: A DNA-binding domain that is present in some BTB proteins,
for example PLZF and FAZF.
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CHAPTER 1

Background and Significance

1

INTRODUCTION
This dissertation focuses on the structure and function of a complex that
modifies proteins by adding ubiquitin to them. This small protein is added in a
multitude of complex ways, which then results in the modified protein being
recognizable by many other proteins. The nature of the ubiquitin modification thus
determines the fate of the protein. Our lab has been interested in a particular
complex that accomplishes this called the Cul3 complex or BCR (BTB-Cul3-Rbx1).
The entities that are capable of identifying and then directing the location of
ubiquitination are called E3 ligases.

In this portion of my dissertation, I will

familiarize you with the process of ubiquitination, identify the major players,
introduce what is known about Cul3 and develop some models that provide the
framework for the testable hypotheses presented in subsequent chapters.

UBIQUITINATION
Post-translational modifications (PTMs) play an essential role in nearly all
biological processes. These modifications provide versatile mechanisms for
regulating a vast range of cellular functions through the covalent attachment of a
functional group to a specific cellular target (Beck-Sickinger and Mörl, 2006).
Among several different PTMs, ubiquitination has emerged as the second
most common protein modificatory process, behind only phosphorylation (Suresh
et al., 2016). This process consists of the attachment of a small protein (76 amino
acids) called ubiquitin to substrates and is mediated by the sequential action of
three enzymes, a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme
2

(E2), and a ubiquitin-ligating enzyme (E3). Like most covalent modifications,
ubiquitination is chemically stable and can only be removed by the action of
proteases specialized in isopeptide-processing called deubiquitinating enzymes
(DUBs; Hershko & Ciechanover, 1998). Together, these enzymes generate a
complex signaling code, which targets the modified substrates for different
pathways depending on the ubiquitin branching architecture on the ubiquitin they
are modified with (Varshavsky, 2012). Protein degradation, endocytosis, traffic,
autophagy, cell cycle progression, DNA stability, transcription, and translation are
some of the cellular activities controlled by ubiquitination (Hershko et al., 1983;
Finley, 2009).

BIOLOGICAL SIGNIFICANCE OF THE UBIQUITINATION SYSTEM
Ubiquitination plays a vital role in regulating proteins on the cellular level.
Consequently, aberrations in the ubiquitination process can lead to several human
disorders, including cardiovascular diseases, cancers, inflammatory and
autoimmune

disorders,

neurodegenerative

diseases,

and

developmental

disabilities (Popovic et al., 2014). In the following sections, I will discuss conditions
caused directly by genetic defects in components of the ubiquitin system or whose
progression is modulated by the ubiquitin interaction network.

Molecular mechanisms of ubiquitination dysregulation in cancers
Ubiquitin modifications regulate multiple growth-signaling pathways in the
cell, ranging from DNA replication and repair to chromosomal separation and
3

cytokinesis (Devoy et al., 2005). Given these central roles, it is not surprising that
dysregulation in the ubiquitin signaling process plays a critical role in malignant
tumor development (Senft et al., 2017; Deshaies, 2014). In fact, many critical
cellular targets have been implicated in carcinogenesis and cancer cell survival,
including Cyclin-dependent kinase (CDK)-cyclin complexes, retinoblastoma
protein (Rb), and tumor suppressor p53 (Chen et al., 2004; Kalejta and Shenk,
2002; Pagano et al., 1995).
CDK-cyclin complexes are directly involved in the cell cycle progression,
and disruptions in this process usually lead to genomic instability and uncontrolled
cell growth, which are common characteristics of cancer cells (Ding et al., 2020).
Porteins p53 and Rb belong to a complex protein network responsible for
regulating the cellular response to stress and DNA damage (Love et al., 2013).
However, mutations generally lead to conformational changes in p53 and Rb
structures, which prevent them from being ubiquitinated and subsequently
targeted to degradation by the proteasome. Consequently, the feedback loop that
controls the p53 and Rb cellular levels is disrupted; they accumulate at extremely
high levels in the cells and become unable to suppress further tumor development
(Inoue et al., 2012).
Another important tumor suppressor regulated by ubiquitin modification is
the cyclin-dependent kinase (Cdk) inhibitor p27 (Alessandrini et al., 1997). p27
acts as a negative regulator of the cell cycle by inhibiting the activity of cyclin/cdk
complexes during G0 and G1 phases of the cell cycle. Degradation of p27 is
required to transition from G1 to S phase and occurs through ubiquitination and
4

subsequent degradation by the proteasome (Montagnoli et al., 1999; Tsvetkov et
al., 1999). Several studies have shown that the enhanced degradation of p27 is
observed in many types of aggressive human carcinomas (Vlach et al., 1997;
Bloom & Pagano, 2007), and mutations in the p27 gene have been linked to higher
tumor grade and poor prognosis (Slingerland & Pagano, 2000).

Molecular mechanisms of ubiquitination dysregulation in inflammatory and
autoimmune diseases
Multiple lines of evidence have indicated that the ubiquitin modifications
also play a role in the development of immune and inflammatory responses,
including in the major histocompatibility (MHC) class I antigen processing and NFκB signaling pathway activation (Marfella et al., 2006; Wang and Maldonado, 2006;
Hu and Sun., 2016). MHC class I molecules are usually expressed on the cell
surface of nucleated cells and present peptide fragments derived from intracellular
proteins processed by the proteasome (Cascio et al., 2001). In addition, ubiquitin
modifications have been shown to regulate macrophages activity and CD8+ T
lymphocyte metabolism (Cascio et al., 2001; Widjaja et al., 2017). Although
ubiquitination has a unique value for the body's immune response, the most critical
link between the ubiquitin system and the immune system is related to NF-κB. NFκB is a master regulator of DNA transcription, cell survival, cytokine production,
and response to infection. In unstimulated cells, NF-κB is actively inhibited when
bound to IκB. Upon stimulation, the phosphorylated IκB is ubiquitinated and
degraded by the proteasome. This process allows NF-kB to translocate to the
5

nucleus, where it mediates the expression of several genes involved in
inflammation (Wang and Maldonado, 2006; Wu et al., 2018). Therefore, any
dysregulation in the ubiquitination process can have drastic effects on the body's
defense mechanisms.

Molecular mechanisms of ubiquitination dysregulation in neurodegenerative
disorders
A growing body of evidence has also associated some chronic
neurodegenerative diseases with increased ubiquitination levels in different neural
structures, such as in the brainstem Lewy bodies of Parkinson's disease and the
neurofibrillary tangles of Alzheimer's disease (Schwartz and Ciechanover, 2009).
Parkinson's disease (PD) is a disorder that affects predominately dopaminergic
neurons in a specific area of the brain called substantia nigra. The cause remains
largely unknown, but researchers are currently exploring ways to identify
biomarkers that can lead to a better understanding of the disease's progress. A
series of physiological and genetic analyses revealed that abnormal functions of
alpha-synuclein impaired the activity of the ubiquitination system, and
accumulation of ubiquitinated proteins in Lewy bodies were observed in the brain
of patients with Parkinson's (Zheng et al., 2016).
In the case of Alzheimer's disease, the most common symptom is the
progressive degeneration of the neural system, which involves the accumulation
and

aggregation

of

neurotoxic

proteins,

such

as

β-amyloid

(Aβ),

hyperphosphorylated tau, and ubiquitinated proteins in vulnerable areas of the
6

brain, such as the hippocampus and cortex. Similar to PD, the ubiquitination
system has been the subject of a recent focus in Alzheimer's disease
pathogenesis, especially after studies have demonstrated that there is a reduction
in proteasomal activity in AD brains and that the UBB+1, a genetic variant of
ubiquitin that is unable to tag protein substrates covalently, is involved in neuronal
degeneration through neuritic beading and mitochondrial stress (George et al.,
2018). These accumulated pieces of evidence in the two most common
neurodegenerative disorders indicate that dysfunctions in the ubiquitination
system are a crucial factor in initiating and aggravating their pathogenesis.

Molecular mechanisms of ubiquitination dysregulation in developmental disabilities
Autism

spectrum

disorders

(ASDs)

are

multifaceted

conditions

characterized by impairments in cognition, communication, and behavior (CDC,
2019). De novo mutations in the Cullin3-RING E3 ligase (Cul3) gene were recently
found in distinct cohorts of autism patients by large-scale unbiased genetic
analysis, making Cul3 one of the top-ranking high-risk autism factors (Kong et al.,
2012). In addition, Cul3 was one of the 107 risk genes identified in a genome-wide
association study (GWAS) of a large population of autism cases (De Rubeis and
Bagni, 2011). Cul3 has also been associated with schizophrenia (SCZ) in a multistage SCZ GWAS spanning 108 conservatively defined loci, and its mutations
overlap with those in ASDs (Schizophrenia Working Group of the Psychiatric
Genomics Consortium, 2014). Although Cul3 is abundantly expressed in the brain
(Dong et al., 2020), there is little information about its binding proteins or the
7

pathways in which this E3 ligase might be involved. Currently, there are no
biomarkers to identify ASDs, and the diagnosis is primarily based on clinical
evaluation. This is problematic because such a lack of specificity presents a
challenge for nosology and the development of more precise therapies. To address
this problem, several ongoing studies are attempting to identify potential
biomarkers, such as Cul3 or other components of the ubiquitin-dependent
proteasome system, that could help with the diagnosis, discrimination, and
prognosis of different ASDs (Arons et al., 2013; Srivastava and Schwartz, 2014;
Faraone et al., 2014; Hallak et al., 2015).

Considering the broad functional spectrum of the ubiquitination network and
the large number of proteins that participate in it, further disease-causing mutations
within the ubiquitination system await discovery. Undoubtedly, technical advances
in detecting ubiquitinated proteins and identifying their respective receptors will
stimulate progress in this research area.

THE COMPONENTS OF THE UBIQUITINATION SYSTEM
The ubiquitination system is directly or indirectly involved in all aspects of
metabolic networks linked to either normal or pathologic pathways. This complex
cellular system encompasses not only the enzymes required for catalyzing the
attachment of ubiquitin to substrates but also the proteins that bind to ubiquitinated
proteins and lead them to their final fate. It also includes activities that remove
ubiquitin independent of, or in concert with, proteolysis of the substrate, either by
8

the proteasome or proteases in the vacuole. Below, the main components of the
ubiquitination network are described, with special attention given to the current
data regarding the modulation of the different parts of this complex cellular system
(Figure 1.1).

Ubiquitin (originally, ubiquitous immunopoietic polypeptide)
Considered the core component of the ubiquitination process, ubiquitin is a
76 amino acid-long protein with a molecular weight of approximately 8.5kDa
(Ciehanover et al., 1978). It was discovered (as a free protein) in 1975 by Gideon
Goldstein and named after the Latin word ubique, which means "everywhere"
because it was found ubiquitously in all eukaryotic cells (Goldstein et al., 1975). At
first, it was assumed that ubiquitin was only present in Eukaryotes (Özkaynak et
al., 1984; Dworkin-Rastl et al. 1984; Bond and Schlesinger, 1987), but recent
studies demonstrated that Archaea and Bacteria have ubiquitin-like systems as
well (Maupin-Furlow, 2013; Pisano et al., 2018). Four different genes (UBB, UBC,
RPS27, and UBA52) encode ubiquitin in mammals, in which genes UBB and UBC
encode linear fusions of 3 and 9 ubiquitin peptides, respectively, whereas RPS27A
and UBA52 encode ubiquitin as an in-frame fusion to a small and large ribosomal
protein, respectively (Özkaynak et al., 1984; Finley et al., 1989; Redman &
Rechsteiner, 1989).
The structure and basic functions of ubiquitin, as well as the components of
the ubiquitination machinery, including the identification of E1, E2, and E3
enzymes (Figure 1.2; Vijay-kumar et al., 1987; Ciehanover et al., 1982; Hershko
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et al., 1983), were elucidated throughout the late 1970s and 1980s by Aaron
Ciechanover, Avram Hershko, and Irwin Rose for which the Nobel Prize in
Chemistry was awarded in 2004 (Nobel Prize in Chemistry, 2004). These
discoveries were followed by a set of studies led by Alexander Varshavsky’s
research group, which revealed the biology of the ubiquitin system, including its
importance for protein degradation in vivo, its physiological roles (in the cell cycle,
DNA repair, protein synthesis, transcriptional regulation, and stress responses),
the origin of its selectivity (specific degradation signals in defective and short-lived
proteins), and its critical mechanistic attributes, such as the poly-ubiquitin chain
assembly and the selectivity of protein degradation (Ciechanover et al., 1984;
Finley et al., 1984; Özkaynak et al., 1984; Bachmair et al., 1986; Jentsch et al.,
1987; Goebl et al., 1988; Bachmair & Varshavsky, 1989; Chau et al., 1989;
Wünning et al., 1989; Bartel et al., 1990; Johnson et al., 1990).

Ubiquitin-activating enzyme (E1)
The ubiquitination cascade initiates with the activation of ubiquitin by a
ubiquitin-activating enzyme (E1) in an adenosine triphosphate-dependent manner.
In vertebrates, the group of ubiquitin-activating enzymes is represented by two
members of the E1 family, Uba1 and Uba6. Uba1 and Uba6 demonstrate distinct
preferences for E2 charging in vitro and have a relative abundance ratio of >10:1
(McGrath et al., 1991; Schulman and Wade Harper, 2009; Clague et al., 2015).
They are ubiquitously expressed in different organisms, ranging from humans to
zebrafish. Several studies demonstrate that the expression of Uba1 is essential
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and, although the Uba6 has also been shown to be capable of activating ubiquitin,
the exceptionally high expression of Uba1 suggests that the ubiquitin pathway
does not rely on activation by Uba6. In fact, Uba6 is only required for embryonic
development and is uniquely responsible for transferring ubiquitin to UbE2Z
(USE1), a Uba6-specific E2 (Jin et al., 2007).
Uba1 is a multidomain enzyme and by far the best-understood example of
E1 in humans (Handley et al., 1991). Each of its domains plays a distinct functional
role: the active and inactive adenylation domains (AAD and IAD) are responsible
for adenylating the C-terminus of ubiquitin (Lake et al., 2001; Lois and Lima, 2005);
the Cys domain (split into first and second catalytic cysteine half domains, SCCH
and FCCH) harbors the catalytic cysteine for thioester bond formation with
ubiquitin (Szczepanowski et al., 2005); and the ubiquitin fold domain (UFD) is the
one involved in molecular recognition of E2s (Huang et al., 2004; Huang et al.,
2007). Due to the variety of cellular functions in which Uba1 is involved, mutations
or a complete loss of the gene have been demonstrated to be lethal in several
organisms (Yang et al., 2007; Groen and Gillingwater, 2015; McGrath et al., 1991).

Ubiquitin-conjugating enzyme (E2)
The second step of the ubiquitination cascade is coordinated by a group of
proteins known as ubiquitin-conjugating enzymes (E2s). They are essential in the
ubiquitination system as they regulate both the topology of the poly-ubiquitin
chains and the processivity of the polyubiquitination reactions (Valimberti et al.,
2015). Some E2s are extraordinarily flexible and accommodate a variety of
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substrates, which allows for a multitude of distinct ubiquitination events and the
generation of diverse substrate-ubiquitin chains. On the other hand, some E2s are
more rigid and incapable of adding ubiquitin to anything other than ubiquitin itself.
This specific subset is exclusively dedicated to extending chains with specific
linkage types (Durfee et al., 2008; Clague et al., 2015; Eletr et al., 2005).
In the human genome, there are 35 E2s exclusively dedicated to ubiquitin
conjugation. They are grouped according to the presence of appendages either Nor C-terminus to the catalytic domain (Classes II and III, respectively), at neither
(Class I), or at both ends (Class IV). They all share a ~150-amino acid conserved
catalytic core domain, known as the ubiquitin conjugation (UBC) domain, which is
the minimal sufficient unit for the E2 enzymatic activity (Figure 1.3). This catalytic
core domain contains the catalytic cysteine responsible for forming the thioester
bond with ubiquitin. The structures of over 32 human E2s (full-length or UBC
domain) have been solved, and the topologies of most are consistent with this
canonical fold (Stewart et al., 2016).

Ubiquitin-ligase (E3)
The last step of the ubiquitination cascade is accomplished by ubiquitinligases (E3s). They are the most critical components of the ubiquitination system
because they are the ones that confer specificity to the process through the
recognition of target substrates. Together, they comprise the largest and most
heterogeneous class in the ubiquitination cascade, with 60–100 putative E3s in
yeast and over 1000 in humans (Berndsen and Wolberger, 2014). They are
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subdivided into three main groups that vary according to the presence of specific
domains and the mechanisms of ubiquitin transfer to the substrates (Figure 1.4;
Morreale and Walden, 2016).
The most abundant group is the RING-type E3 ligase, which is
characterized by the presence of a zinc-binding domain known as RING or by a Ubox fold catalytic domain. The U-box fold catalytic domain adopts a similar
conformation as the RING domain but does not contain zinc (Zheng and Shabek,
2017). RING-type E3s function as a scaffold by orienting the ubiquitin-charged E2
and mediating the direct transfer of ubiquitin to the target substrate. They are
known for their strong tendency to form homodimers and heterodimers, in which
only the homodimeric RINGs can functionally interact with two E2s (one per each
monomer) (Deshaies and Joazeiro, 2009; Morreale and Walden, 2016). Like the
E1s and E2s, several studies have shown that mutations of RING-type E3s, or
dysregulation of their activity, are associated with an array of human disorders.
One well-known example is the development of familial breast and ovarian cancers
when BRCA1, an E3 that plays a critical role in DNA repair, is mutated (Metzger
et al., 2014). Among all the RING-type E3 ligases, cullin-RING ubiquitin ligases
(CRLs) comprise the largest known class. Characterized as multisubunit
complexes, composed of a cullin, a substrate-recognition subunit (SRS), and a
Rbx protein, they are implicated in the regulation of a diverse array of eukaryotic
functions, such as cell cycle control, hypoxia signaling, development, and
response to DNA damage (Bosu & Kipreos, 2008).
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The second-largest group of ubiquitin-ligases is known as Homologous to
the E6-AP Carboxyl Terminus (HECT)-type E3 ligases which, as implied by the
name, are characterized by the presence of the HECT domain. Structurally, these
enzymes are composed of a bulky N-terminus lobe (N-lobe) that contains the E2
binding domain and a C-terminus lobe (C-lobe) that carries the catalytic cysteine
(Huibregtse et al., 1995). They usually catalyze the ubiquitin transfer to the
substrate through a two-step reaction. First, ubiquitin is transferred from the E2 to
a catalytic cysteine on the E3 and then from the E3 to the substrate (Weber et al.,
2019). Like RING E3s, they regulate a wide range of cellular processes and are
involved in many human disorders, such as malignant tumorigenesis (Wolyniec et
al., 2012).
The last and recently described E3 group is composed of ligases that
contain an RBR domain. Similar to HECT, they catalyze ubiquitin transfer through
a two-steps reaction that initiates with the transfer of ubiquitin to a catalytic cysteine
located in the C-terminus domain of the E3 and ends with the ubiquitin being
transferred to the target substrate (Spratt et al., 2014). In addition, this unique
family of E3 ligases includes parkin, a ligase that plays an essential role in the
cellular stress response, whose dysfunction is linked to the pathogenesis of earlyonset Parkinson's disease (Riley et al., 2013).

Deubiquitinating enzyme (also known as Ubiquitin-specific proteases)
The vast majority of cellular proteins are ubiquitinated during their lifetime
(Peng et al., 2003; Wagner et al., 2011; Kim et al., 2011; Swatek & Komander,
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2016) and, in order to maintain the cell homeostasis, ubiquitin must be recycled
once the substrate has been committed to a cellular pathway. This recycling
process is performed by a class of enzymes known as deubiquitinating enzymes
(DUBs), which are modular enzymes that contain catalytic domains and additional
ubiquitin-binding domains, and several protein-protein interactions domains.
These enzymes regulate ubiquitin modifications on proteins in different manners,
ranging from removing ubiquitin from modified proteins, recycling ubiquitin
attached to inappropriate targets, disassembling poly-ubiquitin chains, and
processing proteins before their degradation by the proteasome (Nijman et al.,
2005; Sippl et al., 2011).

26S proteasome
Despite the variety of possible cellular outcomes, a vast range of
polyubiquitinated proteins is targeted to the 26S proteasome for degradation
(Sadowski and Sarcevic, 2010). The 26S proteasome is considered the most
critical non-lysosomal protease in Eukaryotes and is responsible for the
degradation of numerous regulatory proteins in addition to damaged or misfolded
polypeptides (Peters, 1994; Livneh et al., 2016). This protease is found in both the
cytoplasm and the nucleus of all eukaryotic cells and is composed of two
subcomplexes, a 750 kDa proteolytic core particle (CP; also known as the 20S
subunit) and a 900 kDa regulatory particle (RP; also known as the 19S subunit).
The regulatory particle (RP) coordinates the degradation process by recognizing
the polyubiquitinated substrates, unfolding, deubiquitinating, and translocating
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them into the interior of the core particle (CP), where they are degraded to
oligopeptides (Tanaka, 2009).

In summary, the ubiquitination system is critical for the constitutive turnover
of proteins in the nucleus and cytoplasm, as well as for the activation of proteins
involved in virtually every cellular process, including cell cycle progression,
transcriptional regulation, genome integrity, apoptosis, neuronal plasticity, and
immune responses. Much has been learned about its components in the last five
decades, but the mechanisms that regulate each element within this system have
yet to be deciphered.
The most critical event in the entire process is the substrate recognition
step, which is accomplished by the E3 ligase family. Our laboratory has been a
significant player in disseminating the mechanisms of one E3 ligase called Cul3,
which is a member of the cullin family of RING-type E3s. Thus, the work described
in this dissertation focuses on the mechanisms that control the Cullin3-based E3
ligase (Cul3). To enlighten the readers about what is known about the cullin family
of E3 ligases, a discussion of what is known about them is presented below.

CULLIN-RING UBIQUITIN LIGASES (CRLs)
Cullin-RING ubiquitin ligases comprise the largest known class of E3
ligases (Sarikas et al., 2011). The human genome encodes seven different cullins
(Cul1, 2, 3, 4A, 4B, 5, and 7) that, collectively, mediate a vast number of cellular
processes, including transcription, signal transduction, development, and multiple
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aspects of the cell cycle (Kleiger and Deshaies, 2016). CRLs are multisubunit
complexes composed of a cullin, a RING H2 finger protein, a substrate-recognition
subunit (SRS), and an adaptor subunit that links the SRS to the complex (Figure
1.5). Cullin’s C-terminus domain tightly associates with the RING-H2-domain
proteins Rbx1 or Rbx2, which bind the Ubiquitin-conjugating enzymes E2s. The Nterminus domain interacts with a specific set of SRS or adaptor subunits (Kamura,
1999). Three distinct types of adaptor subunits have been described: F-box,
SOCS/BC-box, and DDB1. F-box binds to the SRS Skp1, which binds to Cul1 and
Cul7 (Bosu and Kipreos, 2008). SOCS/BC-box binds to the SRS elongin BC, which
binds to Cul2 and Cul5. Finally, DDB1 binds to an SRS that contains WD-repeats
of a subclass called WDXR, which, in turn, binds to Cul4.
In Cul3, substrates can bind to the Cullin directly (Davidge et al., 2019) or
indirectly through a single polypeptide that binds simultaneously to Cul3 through
an N-terminus BTB-domain and to the substrate through a domain on the N- or Cterminus (Nguyen et al., 2017; Hill et al., 2019). The CRL complexes are generally
inactive, but the covalent attachment of the ubiquitin-like protein Nedd8 causes a
conformational change that switches them on (Duda et al., 2011). Together, cullin
scaffold enzymes have an enormous impact on eukaryotic cell biology, and
mutations in individual cullins have been associated with multiple diseases (Kleiger
and Deshaies, 2016).
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Nedd8
CRLs are activated through a process known as neddylation, in which the
ubiquitin-like protein Nedd8 is covalently attached to a conserved lysine residue
near the Cullin's C-terminus domain (Bosu and Kipreos, 2008). This posttranslational modification plays an essential role in their activities because it can
directly affect their stability, subcellular localization, conformation, and function
(Duda et al., 2011). The peptide NEDD8 is structurally similar to ubiquitin and is
also covalently linked to target proteins through a sequential action of its own set
of E1, E2, and E3 enzymes. In mammalian cells, there is a single Nedd8 E1 (NAE),
two E2s (UbE2M, also known as Ubc12, and UbE2F), and approximately twelve
E3s. NAE resembles a standard ubiquitin-activating enzyme (E1) and consists of
a catalytic subunit (Uba3/Naeβ) and a regulatory subunit (Nae1/Appbp1). Multiple
data sources have shown that UbE2M preferentially promotes neddylation of
Rbx1-associated cullins (Cul1, 2, 3, 4A, and 4B), whereas UbE2F promotes
neddylation of Rbx2-associated cullins (Cul5; Zheng et al., 2021; Li et al., 2019).
Similar to CLRs, the vast majority of Nedd18 E3 ligases contain a RING
domain, such as Rbx1, Rbx2, c-Cbl, Mdm2, and Trim40 (Kamura, 1999; Zuo et al.,
2013; Noguchi et al., 2011; Xirodimas et al., 2004). Dcn1 enzyme is also involved
in Nedd8-CRL conjugation, but unlike other Nedd8 E3s, it does not contain a RING
domain for its catalytic activity (Kurz et al., 2008). Despite its complexity,
neddylation plays an essential role in the ubiquitination cascade because it
increases the affinity of the ubiquitin-charged E2 enzyme to the E3 ligase
(Kawakami et al., 2001) and triggers structural changes that boost the transference
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of ubiquitin to the substrate (Duda et al., 2008). In addition, NEDD8 can also
counteract the association of the CLRs with Cand1 (Liu et al., 2002). Cand1 is a
cullin inhibitor that prevents the binding of Cullin to its substrate-specific subunits
and blocks the lysine residue that becomes neddylated in the active complex
(Goldenberg et al., 2004; Zheng et al., 2002).

COP9 Signalosome
Deneddylation, a process in which Nedd8 conjugates are removed from
Cullins, is mediated by the isopeptidase activity of the metalloprotease CSN5/Jab1
subunit of the COP9 signalosome. This process is physiologically necessary
because it regulates in a coordinated manner the activity of the CLRs, coordinates
the exchange of their adaptor subunits, and prevents their auto-ubiquitination (Qin
et al., 2020; Lingaraju et al., 2014; Cope and Deshaies, 2003). The COP9
signalosome is composed of eight highly conserved subunits, Csn1–Csn8. The
homology of the COP9 signalosome to the eight subunits of the 19S proteasome
lid complex and the three subunits of the eIF3 translation initiation factor complex
suggest a common origin for these three protein complexes. These subunits can
be found encoded in the genomes of many diverse organisms, including humans,
the nematode Caenorhabditis elegans, the fruit fly Drosophila melanogaster, the
mustard weed Arabidopsis thaliana, the fission yeast Schizosaccharomyces
pombe, and the budding yeast Saccharomyces cerevisiae (Bosu and Kipreos,
2008). Several studies have shown that COP9 signalosome is not just implicated
in deneddylation (Wolf et al., 2003). In plants, COP9 signalosome plays a major in
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growth, development, and defense against pathogens, while in yeast, it is involved
in different mating pathways (Schwechheimer et al., 2000), and in yeast, it
regulates different mating pathways (Maytal-Kivity et al., 2002). Studies in human
cells showed that the COP9 signalosome also plays a vital role in signal
transductions and repair of double-strand breaks by getting recruited to doublestrand break sites in a neddylation-dependent manner (Hannß and Dubiel, 2009;
Meir et al., 2015).

BTB-CUL3-RBX1 (BCR) COMPLEX
Cul3, a 768 amino acid-long protein, is a highly conserved CULLIN family
member found in all eukaryotes. This E3 ligase is the core component of a complex
known as BTB-Cul3-Rbx1 (BCR), which comprises the RING finger protein Rbx1,
the Cul3 scaffold, and a Bric-a-brac/Tramtrack/Broad complex (BTB) protein. In
these complexes, the BTB domain-containing protein is responsible for bridging
Cul3 to the substrate in a single polypeptide, while Skp1/F-box or ElonginC/SOCS
heterodimers fulfill this function in the SCF and ECS complexes (Pintard et al.,
2004). Structurally, Cul3 has a highly elongated shape with two distinct functional
domains. The N-terminus domain is composed of helical repeats and is
responsible for the interaction with the BTB-containing protein, whereas the Cterminus harbors Rbx1 and Nedd8, and oversees the ubiquitin-conjugating
enzyme recruitment (Wang et al., 2020).
Initially, it was thought that this E3 ligase was only involved in the antiinflammatory pathway (Du et al., 1998), but after several years of research, it is
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evident that its cellular role is broad. In fact, Cul3 has emerged as a critical player
in the recognition and recruitment of numerous important substrates for
ubiquitination. The Cul3-dependent ubiquitination process is associated with
essential cellular processes, including oxidative stress, cell cycle progression, cell
division, vesicle trafficking, and cell differentiation (Singer et al., 1999; Dubiel et
al., 2017; Chen and Chen, 2016; Cheng et al., 2017). In humans, functional
alterations of Cul3 have deleterious effects on the organism as a whole and usually
lead to the development of several diseases, such as cancer, hypertension, and
muscle disorders (Genschik et al., 2013).

Rbx1
RING box protein-1 (Rbx1), also known as a regulator of cullins-1 (Roc1),
is an essential component of the Cullin E3 ubiquitin ligases. It consists of 108
amino acids with a C-terminus RING-H2 finger domain required for zinc ion binding
and ligase activity (Chen et al., 2000). Rbx1 was initially identified as part of the
Cul1-Roc1 ubiquitin ligase complex, but further analyses indicated that Rbx1 also
binds to different cullin members, including Cul3 (Ohta et al., 1999). Functional
characterization using various model systems demonstrated that Rbx1 is an
essential gene for growth and development. In Drosophila melanogaster, Roc1a is
required for cell proliferation and embryo development. In yeast, it is necessary for
the ubiquitination of the cyclin-dependent kinase inhibitor Sic1 during the G1 to S
cell cycle transition. While yeast cells are completely viable in the absence of Roc1
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(Seol et al., 1999), Drosophila melanogaster Roc1a mutants die as late as
first/second instars (Noureddine et al., 2002).

BTB domain-containing proteins
The BTB protein family was named after the discovery of a ~120 residue
protein-protein interaction motif present at the N-terminus of the Broad-complex
(BR-C), Tramtrack (Ttk), and Bric-à-brac (Bab) proteins of Drosophila
melanogaster (Godt et al., 1993). Besides Drosophila, BTB domain-containing
proteins have also been identified in several other species, such as
Saccharomyces cerevisiae, Arabidopsis thaliana, Caenorhabditis elegans, Mus
musculus, and Homo sapiens (Geyer et al., 2003). The human genome encodes
188 BTB proteins divided into subfamilies according to their additional domains
(Chaharbakhshi and Jemc, 2016; Stogios et al., 2005). Approximately 38 of 188
BTBs have been confirmed as Cul3 substrates adaptors (Zhuang et al., 2009).

The heterogeneity of substrates, substrates adaptors, intracellular and
intercellular processes in which Cul3 is involved demonstrates this E3 ligase's
relevance at both the cellular and organismal level. Although progress has been
truly impressive over the past decades, there is still much that remains to be
discovered to fully understand this intriguing class of Cullin-RING ubiquitin ligases,
including the mechanisms of E2 recruitment and the potential role of the Cul3
substrate adaptors in that process, and the cellular effects of knocking Cul3 out in
kidney cells. In the following sections, I discuss the mechanisms of E2 recruitment
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as well as their interference in the ubiquitin-linkage type selection process. In
addition, I also explain how Cul3 dysregulation leads to the development of a
severe kidney disorder and discuss the implications of using a proteomics
approach to identify novel Cul3 substrates in kidney cells.

MECHANISMS OF E2 RECRUITMENT AND UBIQUITIN-LINKAGE TYPE
SELECTION
The process of conjugating a ubiquitin to a substrate is part of a highly
regulated cellular system. It occurs through the formation of a covalent bond
between α–carboxyl group of the terminus glycine (Gly) residue of ubiquitin and,
typically, the ε-amino group of an internal lysine (Lys) residue of the substrate
(Figure 1.6A). Cellular ubiquitin modifications occur in various forms, which are
usually referred to as "Ubiquitin code" (Komander & Rape, 2012), and these
modifications are interpreted by the cell according to the subcellular localization of
the substrate, the number of ubiquitin peptides attached to the substrate, and the
topology of the ubiquitin chain conjugated to the substrate (Pickart, 2001).
The attachment of a single ubiquitin moiety, known as monoubiquitination,
is the most abundant ubiquitin modification. It regulates DNA repair, transcription,
signal transduction, viral budding, endocytosis, and even proteasomal degradation
(Chen & Mallampalli, 2009; Braten et al., 2016). Followed by the ubiquitin
attachment to the ε-amino group of a target Lys, any of the eight amino groups of
ubiquitin (Met1, Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, Lys63) can be utilized
for the C-terminus attachment of another ubiquitin to form ubiquitin chains of
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variable lengths, linkage types and configurations (homo- and heterotypic
branched ubiquitin chains) (Xu et al., 2009; Zuin et al., 2014). Amongst the different
homotypic ubiquitin chains, Lys48-linked ubiquitin chains were the first to be
identified and are considered the most prevalent ones among all the homotypic
poly-ubiquitin chains (Peng et al., 2003; Swatek & Komander, 2016). This type of
linkage targets proteins for proteasome degradation, which regulates signal
transduction, cell division, stress response, adaptive immune system, and
development (Hershko and Ciechanover, 1998; Wang and Maldonado, 2006; Park
et al., 2007).
The Lys63-linked ubiquitin chains are the second most abundant form of
homotypic poly-ubiquitination (Davis & Gack, 2015). Different from Lys48-linked
chains, this type of ubiquitin attachment does not target substrates to degradation.
Instead, it regulates DNA repair or kinase activation, coordinates multiple steps of
intracellular trafficking, and is involved in various forms of autophagy
(Erpapazoglou et al., 2014). The remaining homotypic poly-ubiquitin chains are
known as atypical, which include all variations of the poly-ubiquitin structure except
for the classical Lys48 polyubiquitination. Although there has been a large body of
data about Lys11 and Lys63, the other types of ubiquitin attachment represent a
still-poorly understood set of molecular signals. More experimental data are
needed to establish their cellular functions and mechanisms of chain assembly.
(Figure 1.6B; Husnjak and Dikic, 2012).
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Roles of E2s during ubiquitin chain assembly
The assembly of ubiquitin chains is usually initiated by transferring the first
ubiquitin to a Lys residue on the substrate. Subsequently, the E2–E3 pair switches
to chain elongation mode, in which additional ubiquitin proteins are attached to the
substrate-linked ubiquitin. The attachment of another ubiquitin to the Lys residue
in the substrate or the ubiquitin is often controlled by the E2s, which contradicts
their early image as simple carriers of activated ubiquitin. Indeed, as discussed
below, substantial evidence supporting their multiple cellular roles, which places
them at a central position within the ubiquitination system.
First, E2s have the ability to determine the specificity of ubiquitin-linkage as
well as the length of the attached ubiquitin chains. Some of them preferentially
transfer ubiquitin to a Lys in the substrate to initiate ubiquitin chain formation,
especially those of the UbE2D family (Kirkpatrick et al., 2006). In contrast, others
are powerful chain-elongating factors (Windheim et al., 2008), which often depend
on the type of linkage used to attach the first ubiquitin to the substrate. For
instance, UbE2T attaches ubiquitin to multiple lysine residues in its substrate but
lacks any ubiquitin chain extension activity (Alpi et al., 2008), whereas the Lys11specific chain-elongating E2 UbE2S lack the capability for ubiquitin chain initiation
(Williamson et al., 2009). Even though a few E2s can catalyze both tasks, such as
the yeast E2 Cdc34 (Verma et al., 1997), it seems that a collaboration between
chain-initiating and chain-elongating E2s is critical for the rapid assembling of polyubiquitin chains.
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Secondly, E2s are also responsible for controlling the processivity of
ubiquitin chain formation, which is defined as the number of ubiquitin molecules
transferred to a growing chain during a single round of substrate association with
an E3 (Ye & Rape, 2009). The faster the processivity of chain assembly, the higher
the chances that the substrate will have a ubiquitin chain that is long enough to be
recognized by the substrate receptors present in the proteasome or any other
cellular structure. Thus, E2s have evolved several strategies to enhance the
processivity efficiency, which includes recognizing specific substrate motifs for
rapid ubiquitin chain initiation, oligomerization of charged E2s, and preassembly
of ubiquitin chains on their active sites (Williamson et al., 2009; Brzovic et al., 2006;
Li et al., 2007).
Lastly, several E2s can also connect ubiquitin molecules in a defined
manner by modifying specific lysine residues in ubiquitin. This usually requires a
non-covalent interaction between an E2 and the acceptor ubiquitin, which exposes
a specific lysine on the acceptor ubiquitin to the active site of the E2 charged with
the donor ubiquitin. For instance, UbE2K, UbE2R1, and UbE2G2 catalyze Lys48linked chains, whereas UbE2N–UbE2V1 complex links ubiquitin molecules
through Lys63 (Bremm & Komander, 2011; Choi et al., 2016; Stewart et al., 2016).
Unlike the E2s mentioned above, UBE2D does not confer linkage specificity and
instead synthesizes ubiquitin chains of all possible linkages (Brzovic et al., 2006).
This preference for a specific Lys in ubiquitin is probably a result of the E2 orienting
the acceptor ubiquitin in a way that exposes the chosen Lys to its active site
(charged with the donor ubiquitin; Eddins et al., 2006).
26

In summary, by determining the length, the topology, and the processivity
of ubiquitin chain assembly, E2s play a significant role in coordinating the
outcomes of the ubiquitination process and, consequently, the fate of ubiquitinated
proteins. However, despite all this progress, there are still many questions that
remain answered, including:

(1) Can cullins (or E3 ligases) be involved in E2 selection?
(2) What other components besides Rbx1 can be used for the recruitment
and binding to E2 enzymes?
(3) How does the BTB-Cul3-Rbx1 (BCR) complex select E2s?

Shedding more light on the mechanisms of E2 selection and recruitment as
well as their interaction with the BCR complex will help improve our understanding
of protein homeostasis and cellular signaling.

FAMILIAL HYPERKALEMIC HYPERTENSION (FHHt)
Familial hyperkalemic hypertension (FHHt) is an inherited disorder
manifested by hyperkalemia and hypertension caused by the hyperactivation of
sodium chloride cotransporters (NCC) that are expressed exclusively in the renal
distal convoluted tubule (DCT; Mayan et al., 2002; Isobe et al., 2012). During the
past two decades, considerable efforts have been taken to identify the proteins
involved in FHHt, which revealed Cul3, its substrate adaptor KLHL3, and its
substrates WNK1 and WNK4 as the major players in this disease. Autosomal
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dominant mutations in Cul3 cause the most severe form of FHHt, but mutations in
WNK1, WNK4, and KLHL3 can also lead to FHHt (Cornelius et al., 2018; LouisDit-Picard et al., 2012; Boyden et al., 2012).
The characterization of the functional roles of KLHL3, WNK1, and WNK4 in
the regulation of NCC in the DCT has opened new and exciting areas of research
that revolutionized our understanding of FHHt. However, a comprehensive
understanding of all the roles of Cul3 in this disorder is far from reach. For instance,
disruption of Cul3 in renal epithelia enhances WNK abundance and
phosphorylation of NCC, but it also had other effects (Saritas et al., 2019). These
included loss of expression of the water channel Aquaporin 2 leading to polyuria
and renal injury (Suzuki et al, 2017). Moreover, Cul3 knockouts have unique
phenotypes and phenotypic severities not seen in knockouts of its known
substrates (Cornelius et al, 2018). In summary, other substrates and different
pathways than Klhl3-Wnk1/Wnk4 are likely contributing to the phenotypic
difference observed in Cul3 knockouts. In that regard, a comprehensive
proteomics screen of Kidney-Specific (KS)-Cul3 knockout cells may help to identify
candidate Cul3 targets and pathways that possibly contribute to the initial renal
injury observed in FHHt. Furthermore, a proteomics approach is superior to
screening by Western blot and immunofluorescence approaches since it
circumvents testing and validating antibodies for the >40 known Cul3 adaptors.
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DISSERTATION SIGNIFICANCE
The heterogeneity of Cul3 substrates, intracellular and intercellular
processes, and physiological systems demonstrates the importance of the Cul3based E3 ligase. During the past two decades, considerable efforts have been
taken to study Cul3, which has led to the discovery of the BCR complex (Pintard
et al., 2004), the regulation by neddylation and deneddylation (Bosu and Kipreos,
2008), and the cellular processes in which the BTB domain-containing proteins are
involved (Stogios et al., 2005). However, even with all this progress, much remains
to be discovered to fully understand the nature of this intriguing regulatory axis.
The work presented here addresses some of the aspects of the function of
Cul3 and has two primary goals: (1) elucidation of the mechanism of E2
recruitment and the potential role of the BTB domain-containing proteins in that
process, and (2) identification of novel Cul3 substrates in kidney cells by taking
advantage of newly acquired Cul3 knockout cells. This dissertation is organized
into four sections: Chapter 1 provides background information on the ubiquitination
system, Cul3-based E3 ligase, and its regulatory pathways. Chapter 2 describes
a series of experiments focusing on a hypothesis that BTB domain-containing
proteins help the complex identify substrates may also participate in the selection
of the E2 enzyme. Chapter 3 describes a proteomics approach to testing the
hypothesis that Cul3 regulates yet unidentified additional substrates in kidney cells.
Finally, chapter 4 discusses future directions that should provide a further
understanding of the mammalian Cul3-based E3 ligase.
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Figure 1.1 – The ubiquitin-dependent proteasome system: This diagram illustrates the
fundamental design of the ubiquitination process. The coordinated activity of ubiquitin-activating
(E1), ubiquitin-conjugating (E2), and ubiquitin-ligating enzyme (E3) is required for ubiquitin
attachment to the target protein. Deubiquitinating enzymes (DUBs) remove ubiquitin from modified
proteins or disassemble unanchored (free) ubiquitin chains. The polyubiquitinated protein is
recognized and bound by the 19S subunit and degraded by the 20S subunit of the 26S proteasome.
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A

B

Figure 1.2 – Structure of Ubiquitin refined at 1.8 Å resolution: This diagram depicts two different
views of the peptide. A) Structure view: ubiquitin contains several secondary structures that are
found throughout the peptide, including three and one half turns of α-helix, a short 310 helix, a
mixed β-sheet with five strands and seven reverse turns. B) Surface view: ubiquitin contains a
hydrophobic core, three hydrophobic residues found on the α-helix, and 11 of the 13 hydrophobic
residues from the β-sheet are involved in constructing this hydrophobic core. The main contributor
to the ubiquitin stability is the huge number of hydrogen-bonding interactions observed. The whole
structure of ubiquitin undergoes significant hydrogen bonding, aside from the COOH terminus
(Vijay-kumar et al., 1987).
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Figure 1.3 – Overall structure of different E2s: Cartoon diagram of a variety of ubiquitinactivating enzymes. The four classes of E2s are colored as follows: class I in green, class II in light
blue, class III in pink, and class IV in orange. The appendages are represented by the black lines.
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Figure 1.4 – Structure of 3 classes of E3s and their mechanisms of ubiquitin transfer: E3
ligases are classified into three groups, depending on their mode of action. RING-type E3 ligases
(left) transfer ubiquitin directly from an E2 cystine to a lysine residue of the target substrate. HECTtype E3 ligases (middle) conjugate ubiquitin in two steps, starting with a ubiquitin being transferred
from an E2 cystine to a catalytic cystine of the HECT domain, followed by the transfer to a lysine
residue of the target substrate. RBR-type E3 ligases (right) have a similar mechanism of HECT,
despite being structurally different, and also conjugate the ubiquitin in two steps, starting with a
ubiquitin being transferred from an E2 cystine to a catalytic cystine of the RING 2 domain, followed
by the transfer to a lysine residue of the target substrate (Metzger et al., 2012).
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Figure 1.5 – Structures of multisubunit Cullin RING-type ligase (CRLs) complexes: Diagrams
of the Cul1 (A), Cul2 (B), Cul3 (C), Cul4 (D), Cul5 (E), and Cul7 (F). They are known as multisubunt
complexes, which are composed of a scaffold protein known as Cullin, a substrate adaptor subunit
on their N-terminus, and a Ring box protein on their C-terminus. They are generally inactive, but
the covalent attachment of a protein called Nedd8 (N8) causes a conformational change that
switches them on. Cul1 and Cul7, which are commonly known as SKP1-Cullin-F-Box (SCF)
proteins, recruit substrates through a substrate adaptor subunit composed of Skp1 and an F-box
protein. Cul2 and Cul5 recruit substrates through a substrate adaptor composed of Elongin-BC.
Cul3 recruits substrates through a substrate adaptor subunit composed of BTB-domain-containing
proteins. Cul4 recruit substrates through a substrate adaptor subunit composed of the DNAdamage-binding-protein 1(DDB1) and a DDB1-binding WD40 protein.
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CHAPTER 2

Substrate selection subunits of the Cul3 E3 ligase participate in E2 binding
and selection
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INTRODUCTION
Ubiquitination is a process mediated by the sequential action of three
different enzymes: a ubiquitin-activating (E1), a ubiquitin-conjugating (E2), and a
ubiquitin-ligating (E3) enzyme. The coordinated activity of these three enzymes is
required for the successful attachment of the ubiquitin to the target substrate
(Figure 1.1; Hershko et al., 1983; Komander, 2009). Ubiquitin E3 ligases are
considered the most critical components of this system because they are the ones
that confer specificity to the ubiquitination process. Cullin-RING ubiquitin ligases
(CRLs) represent the largest family of E3 ligase in eukaryotes, and among the
seven CRLs coded in the human genome, Cullin3 (Cul3) is by far one of the bestunderstood (Deshaies and Joazeiro, 2009; Morreale and Walden, 2016).
Cul3, a 768 amino acid-long polypeptide, is the core of a complex known as
BTB-Cul3-Rbx1 (BCR), which also comprises the RING-box protein 1 (Rbx1) that
is responsible for the ubiquitin-conjugating enzyme (E2) recruitment and a Bric-abrac/Tramtrack/Broad protein (BTB) that functions as a bridge between Cul3 and
the substrate (Ohta et al., 1999; Pintard et al., 2004; Stogios et al., 2005).
Structurally, Cul3 has three domains, an N-terminus domain is composed of helical
repeats that is responsible for the interaction with the BTB domain-containing
protein, the C-terminus domain that binds Rbx1 and Nedd8, and is in charge of the
ubiquitin-conjugating enzyme recruitment, and a stalk domain that connects them
(Wang et al., 2020).
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Cul3-dependent ubiquitination affects many substrates that are involved in
a variety of cellular processes including oxidative stress, cell cycle progression,
cell division, vesicle trafficking, and cell differentiation (Singer et al., 1999; Dubiel
et al., 2017; Chen and Chen, 2016; Cheng et al., 2017). In humans, mutations in
the Cul3 gene have deleterious effects and can lead to contributing to diseases
such as cancer, hypertension, and muscle disorders (Genschik et al., 2013).
The heterogeneity of substrates, physiological systems, intracellular and
intercellular processes in which Cul3 is involved demonstrates this E3 ligase’s
relevance at both the cellular and organismal level. Although progress has been
truly impressive over the past decades, there is still much that remains to be
discovered to fully understand the structure and function of this intriguing class of
Cullin-RING ubiquitin ligases. It has been determined by others that cullins bind
E2s via the Rbx1 protein that is, in turn, bound to the cullin C-terminus. We
reasoned that since substrates are always ubiquitinated with a specific type of
branching (see chapter 1), the E2 selection must somehow “be aware” of the
substrate identity. We suggest that the substrate selection subunit is also involved
in E2 selection. Thus, we focused on testing the hypothesis that the N-terminus
BTB domain-containing proteins bound to substrate collaborate with the Cterminus E2 enzymes to assist with substrate recognition.
In previous work in our lab, we developed cullin chimeras in which we fused
the N- or C-terminus portion of Cul1 to the N- or C-terminus portion of Cul3 (Figure
2.1; Mitchell, 2014). In this work, we determined that the chimeric molecules had
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the predicted binding characteristics based on their domain structure. We then
determined that the wild type versions of Cul1 and Cul3 had differential
preferences for different E2 enzymes by screening a large panel of human E2
proteins.

Armed with that information, we observed that the cullin chimeras

containing the N-terminus of Cul3 retained the binding ability of the wild-type Cul3
for BTB domain-containing proteins. Lastly, we tested the hypothesis that BTB
domain-containing proteins either helped or were required for E2 binding and we
determined that the substrate adapter BTB domain-containing protein was also
required for the binding interaction to occur. Thus, our hypothesis that the E2
selection was, in part, mediated by the substrate adaptor was borne out.

RESULTS
Engineered cullin chimeras: The cullin-based E3 ligases’ basic architecture is
shared amongst the seven known CRL complexes (Figure 1.5). Much attention
has been placed on the substrate-recognition subunit (SRS) and the substrate
selection process, but very little has been directed to the process of how E2s are
selected. To better understand what makes each cullin complex unique, we used
in this study two cullin chimeras with Cul1 and Cul3 that were previously designed
and constructed by Jennifer Mitchell (2014). The two chimera constructs were
named according to the domain of Cul3 that was replaced by that of Cul1. Thus,
they are denoted Cul1 NTD and Cul1 CTD (Figure 2.1A). We tested the constructs
for expression by transfection in mammalian cells, and they both expressed
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normally and were neddylated as efficiently as their non-chimeric counterparts
(Figure 2.1B). Neddylation is a good indication of proper folding of the C-terminus
because it requires binding by Rbx1, binding by the Nedd8 E2 and proper
orientation of the domain to occur (Read et al., 2000; Pintard et al., 2003; Pan et
al., 2004).
The chimera possessing the N-terminus of Cul3 binds BTB adapter proteins:
The observation that the chimeric proteins were neddylated provides evidence that
they are probably folding properly at their C-terminus domains. We then tested the
chimeras’ N-terminus domain binding specificity by examining binding to substrate
adaptor subunits, BTB domain-containing proteins for Cul3 and Skp1 for Cul1. As
we hypothesized, the chimeras containing the Cul3 N-terminus domain bound the
BTB domain-containing proteins Kctd6 and Klhl3, as well as the Cul3 wild-type
construct, (Figures 2.2A and 2.2B, lanes 3 and 5), whereas the constructs
containing the Cul1 N-terminus did not (Figures 2.2A and 2.2B, lane 4).
Conversely, we tested for binding to Skp1, and only the Cul1 wild-type and Cul1
N-terminus constructs bound it (Figure 2.2C, lanes 2 and 4). These data are
consistent with the N-terminus folding properly and demonstrated that the
chimeras maintained the specificity of donor cullin domains.
Cul1 and Cul3 exhibit differential binding to E2 enzymes: E2 enzymes have
been shown to interact with the highly conserved C-terminus domain of cullins via
the RING protein 1 (Rbx1). They work together with CRLs to attach ubiquitin
molecules to substrates and regulate both the topology of the polyubiquitin chains
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(that is, they determine the type of branching and therefore the fate of the
substrate) and the polyubiquitination reactions’ processivity. There are 40
ubiquitin-conjugating enzymes encoded in the human genome (Figure 1.3). While
a growing number of studies have characterized different E2-E3 pairs, little is
known about the specificity of these interactions. Here we investigated the binding
interactions between E2 enzymes and wild type Cul1 or Cul3 in transfected cells
to begin to create a picture of the potential binding interactions of the wild type
enzymes. We observed that two E2 enzymes (UbE2B, and UbE2F) bound to both
Cul1 and Cul3 (Figure 2.3B), while five others (UbE2C, UbE2D1, UbE2D2,
UbE2E2, and UbE2G1) did not bind to either cullin (Figure 2.3A). However, two of
the ones we examined (UbeE2E1 and UbE2E3) displayed selectivity: UbE2E3
bound Cul1 and not Cul3 and UbE2E1 bound Cul3 and not Cul1 (Table 2.1). This
selectivity was then explored further by mapping the regions of Cul3 required to
specifically select an E2.
The BTB binding region of Cul3 is required for binding to E2 enzymes: Since
we had observed that UbE2E1 binds to exclusively to Cul3, we wanted to
determine which part of Cul3 was required for UbE2E1 binding. To investigate this,
we performed co-transfections and co-immunoprecipitation experiments to
examine binding interactions between this E2 and chimeric cullins or a Cul3 mutant
that cannot bind to BTB domain-containing proteins. The current model of CRL
assembly suggests that E2 enzymes interact with cullin-based E3 ligases via
interaction with the ring domain protein Rbx1 in the C-terminus domain of cullins.
68

Since UbE2E1 was able to bind to Cul3 and not to Cul1, we expected that the Cul3
chimera containing the C-terminus of Cul1 would not be able to bind this E2. We
were surprised to see the opposite (Figure 2.4, lane 1). This observation suggests
that the N-terminus domain of Cul3 confers specificity for binding to this E2.
Further, we expected that replacing the N-terminus domain of Cul3 with that
of Cul1 would have little effect on the binding of this E2, as the current model
suggests that the N-terminus domain is not involved. Surprisingly, replacing the Nterminus domain of Cul3 with Cul1 diminished the binding (Figure 2.4, compare
lanes 1 and 2). Moreover, the Cul3 mutant lacking residues involved in BTB protein
binding (Cul3D51-67) also significantly diminished binding (Figure 2.4, compare
lanes 1, 2, and 3). Taken together, these results suggest that the N-terminus,
specifically the BTB binding region, is required for the binding of the UbE2E1 to
Cul3. This is consistent with our hypothesis that the BTB substrate adapters or the
N-terminus domain of Cul3 itself are somehow involved in recruiting certain E2s to
the Cul3 complex.
UbE2E1 is not likely a Cul3 substrate: Alternatively, another possibility is that
UbE2E1 is not serving as a ubiquitin-conjugating enzyme with Cul3 but is instead
bound to Cul3 as a substrate (See model, Figure 2.5A and 2.5B). Since substrates
are recruited to the Cul3 complex by BTB proteins in the N-terminus domain, this
could explain the observation that the BTB binding domain of Cul3 is required for
this E2 to bind. We have examined this in many ways for Cul3 substrates in the
past, including co-transfection to determine if levels of the substrate decrease
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when Cul3 is present and if it is ubiquitinated, as well as transfection into WT vs
Cul3 KO cells (McEvoy et al., 2007; Davidge et al., 2017). Here we show the
results of one such experiment in which we examined UbE2E1 expression levels
in wild-type and Cul3 knockout (KO) cells. As shown in Figure 2.5, the amounts
of UbE2E1 are the same in the presence and absence of Cul3, which would be
consistent with the idea that Cul3 is not likely to be involved in UbE2E1 degradation
(Figure 2.5C, compare lanes 1 and 2).
BTB adapter proteins can bind E2s: Since our hypothesis stated that the BTB
domain-containing protein that acts as a substrate adaptor may also participate in
E2 binding to help select the correct E2, we examined the ability of UbE2E1 to bind
four BTB domain-containing proteins, Kctd6, BTBD1, SPOP, and KLHL3, that were
previously shown to interact with Cul3 (Xu et al., 2002; Ohta et al., 2013; Smaldone
et al., 2015; Gladwyn-Ng et al., 2015; Gschweitl et al., 2016). We found that
UbE2E1 bound to only Kctd6 (Figure 2.6, lane 2). This experiment revealed a
novel interaction between E2 enzymes and BTB domain-containing proteins that
have not been observed before. Therefore, this result is consistent with our
hypothesis that there is selective binding between BTB proteins and E2s.
Cul3 requires the BTB adapter to bind E2s: In order to examine the functional
role of this novel interaction we chose to look at the cyclin E ubiquitination process
that we discovered and have extensively characterized (Singer et al., 1999;
Davidge et al., 2017). RhoBTB3 is a BTB domain-containing protein that is a
component of Cul3-dependent E3 ubiquitin ligase complex and has been shown
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to target cyclin E for degradation (Lu and Pfeffer, 2013). However, our group
showed that cyclin E could also bind to Cul3 directly and independently of
RhoBTB3 (Davidge et al., 2019). Since RhoBTB3 is not essential for the
Cul3/cyclin E interaction, we speculated that it might be playing another role in the
active complex. We hypothesized that since specific E2 recruitment should play
an essential role for the E3 ligase, RhoBTB3 could be responsible for recruiting
the E2 enzyme that ubiquitinates cyclin E under certain circumstances. If BTB
proteins are involved in E2 selection, it will ensure that the proper E2 is recruited
to form the correct ubiquitin linkage for a given substrate. To test this hypothesis,
we examined the binding of Cul3 and RhoBTB3 to the E2 enzyme UbE2E1.
Consistent with our hypothesis, we observed that both RhoBTB3 and Cul3
could bind to UbE2E1 (Figures 2.7A lane 2 and 2.7B lane 2, respectively). We then
examined if Cul3 binding to UbE2E1 requires the BTB domain interacting region
on Cul3. We observed that UbE2E1 could not bind the Cul3 mutant that is
incapable of binding to BTB proteins, Cul3Δ51-67 (Figure 2.7B, lane 3). This
indicates that the interaction with the E2 enzyme is likely to be entirely mediated
by RhoBTB3. To confirm that Cul3 does not mediate the interaction between
RhoBTB3 and UbE2E1, Cul3 knockout (KO) cells (Ibeawuchi et al., 2015) were
used to analyze binding of RhoBTB3 and UbE2E1 to determine if Cul3 was
essential for this interaction. As can be seen in lanes two and four of figure 2.7A,
RhoBTB3 binds to the E2 enzyme in the absence of Cul3 (Figure 2.7A, lane 4) to
the same degree that the two proteins bind in the presence of Cul3 (Figure 2.7A,
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lane 2), indicating that Cul3 is not required for the BTB to interact with the E2.
Together these results demonstrate that a BTB protein, in this instance RhoBTB3,
can interact with an E2 enzyme independently of Cul3 and may enhance E2
binding in vivo. Next, we tested the hypothesis that RhoBTB3 in combination with
UbE2E1 boosts the degradation of cyclin E in vivo.
Substrate levels reduced in the presence of Cul3-BTB-E2 complex: To test
this hypothesis, we performed co-transfections experiments to examine the
repercussions of RhoBTB3 and UbE2E1 overexpression on cyclin E degradation.
As shown in Figure 2.8, the expression levels of cyclin E are reduced in all lanes
in which UbE2E1 is present, indicating that this E2 might boost the degradation of
cyclin E (Figure 2.8, lanes 3, 5, 7, 8, and 9). We also observed that in the presence
of the Cul3-RhoBTB3-UbE2E1 complex, cyclin E levels are 50% lower than the
lane that contains the Cul3 Δ51-67 mutant that is incapable of binding to BTB
proteins (Figure 2.8, compare lanes 8 and 9). These results suggest that the
recruitment of the correct E2 by the BTB adapter may enhance the degradation of
the substrates.

DISCUSSION
The ubiquitin-dependent proteasome system (UPS) is an elaborate and
highly regulated cellular system that controls the attachment of ubiquitin to a target
substrate. Once ubiquitin is attached to the substrate, seven internal lysine
residues (Lys6, Lys11, Lys27, Lys33, Lys29, Lys48, and Lys63) (Xu et al., 2009)
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on the ubiquitin molecule provide conjugation sites for other ubiquitin molecules
and lead to the formation of different polyubiquitin chains that range from a more
linear (Lys6, Lys11, and Lys63) to a more compact and branched (Lys27, Lys29,
Lys33, and Lys48) conformation (Pickart, 2001). This diversity in architecture of
shape is known as the “ubiquitin code” and, through the recognition of specific
ubiquitin receptors, determines the fate of the ubiquitinated substrates (Husnjak
and Dikic, 2012). For example, a polyubiquitin chain with lysine 48 linkages is
branched and a signal for protein degradation (Chau et al., 1989; Thrower et al.,
2000), while lysine 63 linkages are linear and involved in the DNA repair pathway
(Figure 1.2; Spence et al., 1995; Hofmann and Pickart, 1999; Hoege et al., 2002).
Ubiquitin-conjugating enzymes (E2s) play a critical role in this lysine selection
process, as they regulate the position of the lysine residue chosen for the
attachment and the type of ubiquitin linkage that will be produced (Valimberti et al.,
2015).
UbE2E1, also known as UbcH6, attaches ubiquitin to substrates using
lysine 48. Studies have been shown this E2 can interact with multiple proteins,
such as Ataxin 1, NEDD4, and TRIM21 (Hong et al., 2008; Anan et al., 2001;
Anandapadamanaban et al., 2019), is involved in different physiological processes
(Plafker et al., 2004; Malakhova & Zhang, 2008; Hong et al., 2008) and has been
recently identified as a prognostic factor in acute myeloid leukemia (Luo et al.,
2016). Despite the considerable efforts that have been taken to study this E2, little
is known about the specificity of interactions between this E2 and different cullins.
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Here, we have demonstrated that UbE2E1 preferentially binds Cul3 and is
unable to interact with Cul1 (Figure 2.3), and the region of Cul3 required for binding
to UbE2E1 is the BTB domain binding region, not the C-terminus domain, as has
been suggested by the current models (Petroski & Deshaies, 2005; Bosu &
Kipreos, 2008; Deshaies & Joazeiro, 2009; Metzger et al., 2014). Thus, these
observations do not align with the current model of how cullin E3 ligases interact
with E2s. Some precedence for alternative E2 recruitment has been shown by our
group, however this was only demonstrated in bacterially expressed proteins
(Plafker et al., 2009). The same study also demonstrated that UbE2E1 and
UbE2E2 bind the N-terminus of Cul3 in vitro, suggesting that interaction with the
N-terminus of cullin complexes may be a trait shared by all class III E2s.
Our study also revealed a previously unreported binding interaction
between UbE2E1 and the BTB domain-containing protein Kctd6 (Figure 2.6). The
observations that UbE2E1 requires the BTB binding region to bind Cul3 and
interacts with the Cul3 substrate adapter Kctd6 can be explained in more than one
way. One possibility is that UbE2E1 is not serving as a ubiquitin-conjugating
enzyme but is instead recruited by Cul3/Kctd6 as a substrate. We partially
addressed this possibility by showing that the expression levels of UbE2E1 in wild
type and Cul3 KO cells are the same, thus Cul3 probably does not participate in
the UbE2E1 ubiquitination and degradation (Figure 2.7). Another possibility,
supporting our model, is that UbE2E1 is recruited to the Cul3 complex by specific
BTB domain-containing proteins such as Kctd6. Thus, we suggest that certain BTB
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domain-containing proteins may bind both the E2 and the substrate, ensuring
proper ubiquitin branching.
Here, we demonstrated that RhoBTB3 is also able to bind to UbE2E1, both
in the presence and absence of Cul3, and this interaction diminishes the cellular
levels of cyclin E (Figure 2.8). These findings are significant as they confirm that
Cul3 substrate adaptors participate in the E2 selection process to mediate a
functional complex. This also would help to explain how Cul3 can form a variety
of ubiquitin chain linkages as different E2s are associated with this process. The
revelation that the Cul3Δ51-67 mutant, which cannot bind BTB proteins, is
incapable of binding UbE2E1 (Figure 2.7) presents a second piece of information
supporting the idea that BTB domain-containing proteins are necessary for E2
selection to occur.
Until now, models have suggested that the recruitment of E2s for the
ubiquitin-conjugation process occurs independently of the substrate that is being
ubiquitinated and involves the C-terminus of Cul3 interacting with the ubiquitinconjugating enzyme (E2) and the N-terminus interacting with and recruiting the
substrate via a BTB domain-containing protein (Figure 2.9A). In the work reported
here, we have made four important discoveries about this subject. First, we
demonstrated that Cul1 and Cul3 have differential binding preferences for E2s
(Figure 2.7). Second, we determined that the cullin chimeras containing the Nterminus of Cul3 retained the binding ability of the wild type Cul3 (Figures 2.2 and
2.4). Third, UbE2E1 preferentially binds to Cul3 rather than Cul1 and a BTB
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adaptor protein is required for this interaction to occur (Figures 2.4, 2.7, and 2.8).
Fourth, certain E2 enzymes might be able to interact with both termini of Cul3
(Figure 2.9B).
Lastly, several experiments remain to be done to further characterize and
understand this novel selection mechanism. For example, a crucial question that
needs to be addressed is what, if any, role does the previously characterized Rbx1
recruitment play in E2 selection? We have the tools to examine this question, a
mutant that does not bind Rbx1 was created and characterized in our laboratory
and would be an invaluable tool for such an analysis (Wimuttisuk & Singer, 2007).
Another important question that needs to be answered is what region of the Nterminus Cul3 is responsible for the interaction with the E2s? Besides the mutant
that cannot bind to Rbx1, we have at our disposal a variety of other mutants with
specific deletions that would be very helpful in pinpointing the binding region.

MATERIAL AND METHODS
Cell culture and transfections: Cells (HEK293 wild type and Cul3 knockout) were
maintained in DMEM (Gibco™, CAT no. 11965092) supplemented with 10% Fetal
Bovine Serum (Atlas Biological, CAT no. F-0500-A), 1% L-Glutamine (Gibco™,
CAT no. 25030081), and 1% Penicillin/Streptomycin (Gibco™, CAT no.
15070063). Cells were split 1:20 for transfection in 6 cm dishes the night before
transfection. Transfections were performed using the calcium phosphate
precipitation (Jordan et al., 1996). For immunoprecipitations and Western blots,
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cells were harvested 48 hours post-transfection. The amount of plasmid DNA
transfected into each plate varied from 1 to 10μg. All transfected cells were
scrapped and harvested using 600μL of a solution containing 10mL of
radioimmunoprecipitation assay lysis buffer (RIPA) mixed with 1 protease inhibitor
tablet (Thermo Scientific™, CAT no. PIA32953), and then sonicated with an
ultrasonic cell disrupter (VIRTIS VIRSONIC 100) for 15 seconds at 50% power
before being used for immunoprecipitations or western blots. CRISPR knockout
Cul3 HEK293 cells were a gift from Curt Sigmund.
Western

blotting

and

immunoprecipitations:

Western

blots

and

immunoprecipitations were conducted as previously described (Wimuttisuk et al.,
2014). In short, 500μL of the sonicated transfection lysate was added to the
desired antibody in a microcentrifuge tube. 40 μl of RIPA–Sepharose beads
(Thermo Scientific™, CAT no. 101041) were then added to the mixture, and the
immunoprecipitations were placed on a rotator for 2 h at room temperature before
being rinsed with RIPA buffer for 15 seconds at 1500rpm, heated in 15μL of SDSPAGE loading buffer for 2 minutes, and ran on an SDS-PAGE gel. The following
antibodies were used for immunoprecipitations at 1–2μg or at the indicated dilution
for western blotting: monoclonal anti-FLAG (1:1000, CAT no. F3165, SigmaAldrich), monoclonal anti-Myc (9E10) (1:500, c-Myc mouse anti-Human, CAT no.
MA1-980, Invitrogen™), polyclonal anti-c-Myc (A14) (1:500, Santa Cruz
Biotechnology), S-peptide monoclonal antibody (1:1000, clone 6.2, CAT no. MA1981, Invitrogen™), monoclonal anti-HA.11 (16B12) (1:1000, CAT no. MMS-101P77

200, BioLegend), polyclonal anti-HA (1:1000, CAT no. PA1-985, Invitrogen™),
polyclonal anti-β actin (CAT no. AM4302, Invitrogen™), polyclonal anti-Cul3
(Singer et al., 1999; McEvoy et al., 2007), and monoclonal anti-cyclin E (HE12)
(1:100 for transfected samples, CAT no. 32-160-0, Invitrogen™), Goat anti-Rabbit
IgG (H+L) Secondary Antibody, HRP (1:10000 for transfected samples, CAT no.
31460, Invitrogen™), Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary
Antibody, HRP (1:10000 for transfected samples, CAT no. G-21040, Invitrogen™).
Western blots were visualized using myECL™ Imager (CAT no. 62236, Thermo
Scientific™)
Plasmids: 3x-Flag-Cul3 (Sweeney et al., 2020) was used for all Cul3-containing
transfections, including the Cul3 mutant (Cul3Δ51-67). BTB domain-containing
proteins were expressed either using the CS2-Myc-tagged or the CS2+S-tagged
expression vectors (Znosko et al., 2010). E2 enzymes were expressed either in
CS2+HA tagged or CS2+Myc-tagged expression vectors. The chimeric cullins
were cloned into the pCMV-3Tag-6 vector (Mitchell, 2014).
Engineered cullin chimeras: The two cullin chimeras used in this study were
previously designed and constructed by Jennifer Mitchell, 2014.
Quantification of UbE2E1 and cyclin E relative levels: The ImageJ software
was used for the quantification of the relative levels of UbE2E1 and cyclin E bands
shown in figures 2.5 and 2.8, respectively. The quantification reflects the relative
amounts as a ratio of each protein band relative to the lane’s loading control. In
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the UbE2E1 blot, the loading control is in lane 1 (Figure 2.5) and in the cyclin E
blot, the loading control is in lane 1 (Figure 2.8). ImageJ is a Java based (runs on
all operating systems) freeware by Wayne Rasband from National Institute of
Health (USA) and is available for download at: http://rsb.info.nih.gov/ij/
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Figure 2.3 – Cul1 and Cul3 exhibit differential binding to E2 enzymes: HEK 293 cells were cotransfected with Myc-tagged E2 enzymes and FLAG-tagged Cul1 or Cul3. Cells were harvested
after 48 hours. Immunoprecipitation was carried out using a FLAG antibody, and immunoblotting
was used to probe for Myc-E2 binding. (A) E2s that could not bind to either Cul1 or Cul3 (top row).
(B) E2s that could bind to both Cul1 and Cul3 (top row). (C) E2s that could bind only Cul3 (top row)
or only Cul1. The second rows on A show control precipitation with an anti-FLAG antibody. The
lower 2 rows show the expression of the Myc-E2 and FLAG-cullin, respectively.
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Table 2.1 – List of ubiquitin-conjugating (E2) enzymes E2 clones into mammalian
expression vector that were used in the differential binding experiments: Column
one shows the names of the ubiquitin-conjugating enzymes, column two shows the classes
to which they belong, column three shows the lysine they use to attach the ubiquitin to the
substrate (Komander & Rape, 2012), and column four shows the differential binding to
Cul1 and Cul3 based on co-immunoprecipitation (Figure 2.3).

E2 enzyme

Class

Ubiquitin
attachment

Binding to
Cul1

Binding to
Cul3

UbE2B

1

K11, K48, K63

+

+

UbE2D1

1

K48

-

-

UbE2D2

1

K48

-

-

UbE2E1

2

K48

-

+

UbE2E2

2

K11, K48, K63

-

-

UbE2E3

2

K11, K48, K63

+

-

UbE2F

2

Nedd8

+

+

UbE2G1

1

K48, k63

-

-
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Figure 2.4 – Cul3 requires the BTB binding region to interact with E2: Western blot of FLAGtagged chimeric cullins, and a Cul3 mutant transfected in HEK 293 cells with UbE2E1. Cells were
harvested after 48 hours. Immunoprecipitation was carried out using a FLAG antibody, and
immunoblotting was used to probe for Myc-UbE2E1 binding (top panel). The second panel is a
FLAG antibody control and verifies that the immunoprecipitation pulled down FLAG-cullins. The
bottom two panels indicate expression levels of Myc-UbE2E1 and FLAG-cullins, respectively.
Reprinted from “Characterization of Functional Domains of Cul3, an E3 Ubiquitin Ligase, Using
Chimeric Analysis”, by Jennifer Anne Mitchell, 2014, M.Sc. thesis, Biology Department, Portland
State University, p. 67.
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CHAPTER 3

Identification of novel kidney specific Cul3 degradation substrates
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INTRODUCTION
Ubiquitination is a process mediated by the sequential action of three
different enzymes: ubiquitin-activating (E1), ubiquitin-conjugating (E2), and
ubiquitin-ligating (E3) enzymes. The coordinated activity of these three enzymes
is required for the successful attachment of the ubiquitin to the target substrate
(Hershko et al., 1983; Komander, 2009). Cullin-RING ubiquitin ligases (CRLs)
represent the largest family of E3 ligases in eukaryotes. Among the seven CRLs
coded in the human genome, Cullin3-based E3 ligase (Cul3) is one of the moststudied and well-understood enzymes (Deshaies and Joazeiro, 2009; Morreale
and Walden, 2016;).
Cul3 is a highly conserved gene that is expressed in all human organs (The
Human Protein Atlas, 2021; Uhlen et al., 2015; Thul et al., 2017). It is the core
piece of the BTB-Cul3-Rbx1 (BCR) complex, which also comprises the RING-box
protein 1 (RBX1) that is responsible for the ubiquitin-conjugating enzyme (E2)
recruitment and a Bric-a-brac/Tramtrack/Broad complex (BTB) protein that
functions as a bridge between Cul3 and the substrate (Ohta et al., 1999; Pintard
et al., 2004; Stogios et al., 2005).
Several studies have established that Cul3 regulates the progression of
many critical cellular processes by targeting proteins either for 26S proteasomemediated degradation or for non-proteolytic cellular pathways, such as
chromosome segregation, development, cytoskeletal remodeling, and response to
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DNA repair (Dubiel et al., 2017; Chen and Chen, 2016; Cheng et al., 2017;
Furukawa et al., 2003; Chen et al., 2009; Sumara et al., 2007; Moghe et al., 2012;
Mulvaney et al., 2016). Its ultimate disruption results in early embryonic lethality
(Singer et al., 1999). Mutations have been associated with the development of
several

diseases,

such

as

epithelial

cancers,

renal

dysfunctions,

neurodegenerative and muscle disorders (Popovic et al., 2014). Disruption of Cul3
was also associated with increased lysine deficient protein kinase (WNK)
abundance and phosphorylation of the thiazide-sensitive NaCl cotransporters
(NCC) in renal epithelia (Cornelius et al., 2019). These included loss of expression
of the water channel Aquaporin 2, a vasopressin-regulated water-channel protein,
leading to polyuria, renal injury, and dehydration (Suzuki et al, 2017). Importantly,
Cul3 has also been associated with Familial Hyperkalemic Hypertension (FHHt),
also known as pseudohypoaldosteronism II (Shibata et al., 2013; Genschik et al.,
2013; Cuneo and Mittag, 2019).
FHHt is an inherited disorder characterized by hyperkalemia and
hypertension caused by the hyperactivation of sodium chloride cotransporters
(NCC) that are expressed exclusively in distal convoluted tubules of the kidney
(DCT; Mayan et al., 2002; Isobe et al., 2012). Autosomal dominant mutations in
Cul3 cause the most severe form of FHHt, but mutations in WNK1, WNK4, and
KLHL3 can also lead to FHHt (Cornelius et al., 2018; Louis-Dit-Picard et al., 2012;
Boyden et al., 2012). During the past two decades, considerable efforts have been
taken to identify the proteins involved in FHHt. A solid body of work revealed Cul3,
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its substrate adaptor KLHL3, and its substrates WNK1 and WNK4 as the major
players in the disease (McCormick et al., 2014).
Cul3 knockouts shown a unique phenotype severity in the kidney not seen
in knockouts of its known substrates (WNK1, WNK4; McCormick et al., 2014;
Cornelius et al., 2018). Taken together, we hypothesized that there are other
contributing factors besides Klhl3-Wnk1/Wnk4 pathway that leads to this
phenotypic difference. Hence, I proposed to perform an unbiased proteomic
screen to identify candidate Cul3 targets and pathways that may contribute to the
initial renal injury observed in Kidney Specific (KS)-CUL3(-/-) mice, in which Cul3
was deleted only along the nephron. Our group has also observed an increased
abundance of two adaptors with known renal functions, KLHL3 and Keap1, in Cul3
KO cells (McCormick et al., 2014; Watai et al., 2007), thus my approach may also
help to identify more adaptors expressed in the kidney. Therefore, I predict that
CRL disruption would increase the abundances of other renal CRL adaptors in
addition to other potentially important substrates. A proteomics approach is
superior to screening by Western blot and immunofluorescence approaches since
it circumvents testing and validating antibodies for the >40 known CRL adaptors.
I also hypothesized I would identify novel substrates such as aquaporins or
regulators of their activity.
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RESULTS
Validation of the HEK293 wild type and Cul3 knockout cells: HEK293 which
was first derived from embryonic kidneys became a widespread non-cancer cell
model that allowed researchers to use it for KO studies. (Russell et al., 1977). For
my studies, I used wild-type (WT) and a HEK293 variant (Cul3 KO) with a Cul3
deletion performed by CRISPR technology (Ibeawuchi et al., 2015). We have
previously shown that Cul3 KO cells have elevated levels of several known Cul3
substrates (McEvoy et al., 2007; Davidge et al., 2019). In addition to the classic
molecular techniques previously used, I decided to validate the actual cells we
used for the Mass Spectrometry (MS)-based proteomics screen by examining the
endogenous levels of Cul3 in WT and Cul3 KO HEK 293 cells (Figure 3.1A, top
panel). By using Western blots (WB), I observed that the Cul3 levels were
dramatically reduced in Cul3 KO cells. The residual bands that I observed on WBs
were probably a slight amount of cross-reactivity to all the other cullins that run in
the same location on the gel.
To ascertain the change of Cul3 function in the WT vs Cul3 KO cell lines,
both cell lines were transfected with MYC-cyclin E, a well-characterized substrate
of Cul3, to determine its half-life (Figure 3.1B, top panel; Davidge et al., 2019).
Following cycloheximide (CHX) addition, which inhibits protein synthesis in
eukaryotic cells, I harvested the cells every 3 hours for 24 hours. I observed that
cyclin E has a half-life of about 3 hours in the WT cells but a half-life of about 6
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hours in the KO cells (Figure 3.1C). This change is similar to the change we have
observed in mouse fibroblasts that have a Cul3 deletion (McEvoy et al., 2007),
leading to an increase in the half-life of cyclin E.
Quantitative proteomics analysis of cells lacking Cul3: A MS-Based LabelFree Quantitative Proteomics analysis (Zhu et al., 2010) was performed on four
biological replicates of each cell line, as summarized in Figure 3.2. I compared the
relative amount of proteins of the WT and Cul3 KO cells, focusing my attention on
proteins that had spectral counts in all replicates. As shown in Tables 3.1 and 3.2,
approximately 2900 proteins and 13000 unique peptides, respectively, were
identified in each of the eight biological replicates (four WT and four KO) used in
this study. Low data variability and no statistically significant p-values confirm the
reproducibility of the analysis.
Main results of the proteomics analysis: Figure 3.3 summarizes the data
obtained from the MS analysis of both the WT and Cul3 KO cells. The total number
of proteins identified and quantified was 4087. Of those, 3265 were identified in
both cell lines, and only these were considered for subsequent statistical analyses.
We ordered them based on their calculated fold changes (comparing the two
genotypes), performed a t-test analysis, and used p < 0.05 as the cutoff for the pvalue. These three criteria combined were used as the threshold for up- or
downregulation of the proteins identified in our procedure. For instance, if the pvalue was lower than 0.05 and the fold change was lower or larger than 1.5, we
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considered that the protein was differentially expressed. The number of proteins
whose statistically significant fold change was at least 50% compared to the
observed in the WT (p-value ≤ 0.05) was 259. Of these, 77 of the proteins were
upregulated with a fold change ≥ 1.5, and 46 were downregulated with a fold
change ≤ -1.5.
Functional categorization of proteins whose spectral counts were
significantly high or low in KO cells: I used Gene Ontology (GO), a tool that
provides a framework and set of concepts for describing the functions of gene
products across all species, and REACTOME, a tool that identifies biological
pathways that are enriched in a gene list, to predict function of the proteins whose
levels were significantly different (+/−50%) (Thomas, 2003; Jassal et al., 2019).
The GO analysis revealed that, in both groups, the predominant protein class was
metabolite interconversion enzymes, followed by nucleic acid-binding proteins.
This prediction indicated that the majority of proteins with high and low spectral
counts in both cell lines played catalytic or protein-binding roles. The results for the
biological process shown in Figure 3.4 corroborates the similarity between the two
groups observed in the protein class and molecular functional analyses, with most
proteins being implicated in different metabolic or general cellular processes. For
a thorough understanding of the cellular implications of Cul3 absence, I have also
explored the REACTOME biological pathway database to identify potential
pathways that were altered in Cul3 KO cells (Tables 3.3 and 3.4). The analysis
revealed that most proteins with high and low spectral counts were involved in
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nucleic-acid processing, metabolism, or signal transduction processes, which was
in accordance with the results of the GO enrichment analysis (Figure 3.5).

PROTEINS WITH SIGNIFICANT HIGH SPECTRAL COUNTS IN CUL3 KO
CELLS
Identification of potential substrates and pathways that contribute to a more
severe FHHt phenotype observed in Cul3 knockouts: Previously characterized
substrates of Cul3, such as WNK1, RhoA, and RhoB, as well as the Cul3 substrate
adaptor ANKFY1 (Table 3.5; Terker et al., 2018; Cornelius et al., 2018; Chen et
al., 2009; Murakami et al., 2019; Maekawa et al., 2017) shown high spectral counts
in our MS-based proteomic analysis, confirming the reliability of the procedure, and
supporting our strategy of using KO cells to discover novel Cul3 targets, substrate
adaptors, and pathways. The analysis also revealed a subset of proteins with high
spectral counts in the KO cells that have not yet been characterized as Cul3
substrates but have the potential to be (Table 3.6). To further analyze these
proteins, I categorized them based on the three criteria: First, using information
from the literature, I identified where they are expressed and active in the kidney,
and checked if they overlapped with Cul3 expression and activity. Second, I
determined the renal pathways of involvement and predicted if disruptions and
mutations in these pathways could collaborate with the severity of the FHHt
phenotype. Lastly, I searched the literature for information connecting them to Cul3
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function, which would support our hypothesis that they are potential Cul3
substrates. The analysis is described below.

Mitogen-activated protein kinases (MAPKs)
The first of the proteins that meet the three criteria listed above are two
mitogen-activated protein kinases (MAPKs), known as ERK1 and ERK2. Similar
to Cul3, these two enzymes are highly expressed and active in the distal
convoluted tubules (DCT; Cornelius et al., 2019; Capolongo et al., 2019). This
renal colocalization indicates a possibility of physical interaction between them,
which is consistent with them having the potential to be Cul3 substrates. ERK1
and ERK2 are known to mediate cellular responses to injuries and stress in the
kidneys as well as the regulation of the thiazide-sensitive NCC (Ko et al., 2010).
As previously mentioned, upregulation of NCCs is the main cause of the increased
blood pressure and elevation of potassium levels observed in FHHt patients that
are triggered by disruption of Cul3 and, as a result, enhanced activity of its
substrates WNK1 and WNK4 (McCormick et al., 2014). The fact that both WNKs
and ERKs are kinases and control the activity of NCCs in the DCT supports the
hypothesis that the severe phenotype observed in Cul3 knockouts is caused by
simultaneous enhanced activity of multiple substrates, and the ERKs are possibly
part of this regulatory pathway. In addition, Hollstein & Cichowski has shown that
Cul3 loss, drastically attenuated ERK signaling in a study about the regulation of
the NF1 tumor suppressor protein by the BCR complex (Hollstein & Cichowski,
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2013). Taken together, these results support our hypothesis that ERK1 and ERK2
are strong candidates for Cul3 substrates and, in addition to WNK1 and WNK4,
they are likely to regulate the activity of the NCCs. Further studies would be
required to properly understand their roles in the cell.

Syntaxin 4A (STX4A)
Second, I analyzed the vesicle-targeting protein Syntaxin 4a (STX4A),
which, like Cul3, is also expressed in the principal cells of the renal collecting ducts
(CD). Compared to the cytoplasmic Cul3, STX4A is an integral membrane protein
localized to the apical plasma membrane of the CD cells (Cornelius et al., 2019;
Mandon et al.,1996). Regarding its cellular role, STX4A is known to target
Aquaporin 2 (AQP2)–containing vesicles to the apical plasma membrane (Mandon
et al., 1997). Apical plasma membrane faces urine containing lumen of CD. As
previously demonstrated by McCormick, AQP2 levels are reduced in Cul3
knockout mice (McCormick et al., 2014). A possible explanation for this
phenomenon is that, in the absence of Cul3, the expression of RhoA increases.
RhoA, a known Cul3 substrate and a regulator of the cytoskeleton, could prevent
the association of AQP2-containing vesicles with the apical membrane of the DC
cells, which in turn causes disposal of AQP2 in the urine.
My analysis showed that the spectral counts of RhoA were two times higher
in the KO cells while AQP2 levels were zero, supporting the hypothesis that, in the
absence of Cul3, the enhancement of RhoA probably affects the levels of AQP2.
111

RhoA is a well-known Cul3 substrate, STX4A and RhoA have antagonistic roles in
the kidney, and the absence of protein-protein interactions between Cul3 and
STX4A (Rouillard et al., 2016) suggests that STX4A is likely not a Cul3 substrate.
In addition, a study about Syntaxin 1 demonstrated that a novel E3 ubiquitinprotein ligase known as Staring was responsible for targeting Syntaxin 1 for
degradation (Chin et al., 2002), supporting the idea that Cul3 is probably not
involved in the degradation of members of the Syntaxin family. However, we and
many others have shown that multiple E3 ligases target substrates, so it is possible
that STX4A is in fact a substrate.

Gelsolin (GSN)
Thirdly, I analyzed Gelsolin, which is an actin-modulating protein
responsible for promoting actin filament nucleation, as well as severing existing
filaments (Hartwig et al., 1990). Similar to Cul3, it is expressed in the distal
convoluted tubules (DCTs; Cornelius et al., 2019; Lueck et al.,1998; Arai &
Kwiatkowski, 1998), which meets the first criteria to be considered a potential Cul3
substrate. In the kidney, GSN functions as part of the extracellular actinscavenging system, binding and facilitating removal of potentially inflammatory
actins released from injured cells (Shi et al., 2018). The symptoms observed in
FHHt are known to cause severe damage to the kidney cells, which presumably
triggers the release of several inflammatory actins. In response, GSN is activated,
and its scavenging process begins. If GSN was a Cul3 substrate, in a scenario of
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FHHt diagnosis, we would observe an enhancement in GSN levels due to
malfunction in the Cul3. Increase in GSN would lead to a reduction in
proinflammatory actins, and an overall improvement in the kidneys' health. It is the
opposite of what is observed in FHHt. Interestingly, I observe GSN’s 2.6X fold
change, which suggests that Cul3 controls GSN’s cellular levels, either directly or
possibly through the degradation of other yet to be discovered proteins responsible
for GSN degradation. Further analysis will be necessary to identify them.

Other potential Cul3 substrates with less clear associations
I also found two other proteins that are not associated with FHHt but have
the potential to be Cul3 substrates (Table 3.7). The first one is a tumor suppressor
known as BCCIP (BRCA2 and CDKN1A-interacting protein), which is an important
cofactor for BRCA2 in tumor suppression, and a modulator of CDK2 kinase activity
via p21 (Liu et al., 2001). BCCIP is involved in important processes relevant to the
maintenance of genome stability and its downregulation is correlated with the
aggressiveness of brain tumors (Liu et al., 2009). The second one is another tumor
suppressor known as RB1CC1 (Rb1-inducible coiled-coil protein 1), which is a
potent regulator of the RB1 pathway through induction of RB1 (Retinoblastoma 1)
expression (Chano et al., 2002). RB1CC1 is involved in multiple processes such
as cell growth, cell proliferation, apoptosis, autophagy, and cell migration, and its
dysregulation is associated with cell growth and progression of various cancers
(Kontani et al., 2003). Co-immunoprecipitation assays of these two proteins may
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reveal them as promising targets for future studies investigating the role of the
Cul3-based ubiquitin ligase in FHHt development and other pathalogical
processes.

Common domains found among the proteins with significant high spectral
counts: I further characterized the relationship between Cul3 and the proteins that
shown a high spectral count in the analysis by searching for a common pattern of
conserved domains among them. By isolating regions that are conserved in the
proteins with high spectral counts, I wanted to identify common elements that could
be valuable for further functional studies about how Cul3 interacts with other
proteins and for evolutionary studies about how these interactions evolved to fulfil
specialized cellular functions. For instance, previous studies have discovered
members of cullin complexes through their protein-protein interacting domains,
such as F-box proteins in the Cul1 complex, BTB domain-containing proteins in
the Cul3 complex, and DWD proteins in the Cul4A complex (Bai et al., 1996;
Skowyra et al., 1997; Furukawa et al., 2003; He et al., 2006). Furthermore, CullinRING ligases (CRLs) are structurally similar, but there is almost no overlapping
regarding the substrates they ubiquitinate and the structural domains their
substrate adaptors use to connect the substrates to the CRL (Sun et al., 2020).
Here, I identified four domains of interest that will be used in further analyzes:
Ubiquitin-specific protease (UPS) domain, UBC fold domain, leucine-rich repeat
(LRR) domain, and WD40 domain (Table 3.8).
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Ubiquitin-specific proteases (USPs)
Ubiquitin-specific proteases are deubiquitinating enzymes (DUB), which are
proteins responsible for removing ubiquitin from modified proteins, recycling
ubiquitin attached to inappropriate targets, disassembling polyubiquitin chains, and
processing proteins before their degradation by the proteasome (Sippl et al.,
2011). The USP domain consists of a common conserved catalytic core
interspersed at five different points with insertions, some of which are as large as
the catalytic domain itself. These insertions can fold into independent domains that
can be involved in regulating the DUB activity (Ye et al., 2009). The 14 DUB
identified in the KO cells suggests that Cul3 plays an important role in their
expression. There are two possible explanations for this: (1) They might be
substrates of Cul3, so in its absence, their levels increase because they are not
ubiquitinated and targeted for degradation. (2) Cul3 role is broader than targeting
substrates to degradation by the proteasome. In fact, a huge number of its
substrates are involved in regulatory responses or signal transduction pathways.
Therefore, it is possible that the lack of Cul3 halts the ubiquitination of regulatory
molecules involved in controlling the expression and/or degradation of DUB
enzymes. Biochemical verification of the 14 USP identified in this analysis may
help to understand the mechanisms behind their overexpression and may reveal
promising candidates for future studies investigating the role of the Cul3-based
ubiquitin ligase.
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UBC fold domain-containing proteins
Members of the family of ubiquitin-conjugating enzymes (E2s) are
characterized by the presence of a highly conserved ubiquitin-conjugating catalytic
(UBC) fold. Some E2s consist only of the catalytic domain (class I), others have
additional N- or C-terminus extensions (classes II and III, respectively) or both
(class IV) (Figure 1.5; Valimberti et al., 2015). These extensions are involved in
functional differences between E2s, which involve differences in subcellular
localization, stabilization of the interaction with E1 enzymes, or modulation of the
activity of the interacting E3 ligase (Durfee et al., 2008; Clague et al., 2015; Eletr
et al., 2005). Fifteen different ubiquitin-conjugating enzymes were identified in our
analysis (Table 3.8). Initially, we were inclined to characterize them as partners of
Cul3 during the transference of ubiquitin to the substrates, but the data shown in
Figure 2.6 revealed that a few of these E2s did not interact with Cul3. Alternatively,
another possibility is that these E2s are not serving as a ubiquitin-conjugating
enzyme with Cul3 but are instead bound to Cul3 as substrates. Biochemical
verification of these enzymes will help us to expand our knowledge about the
preferential binding of E2s for specific cullins and may reveal promising candidates
for future studies about the major players in the process of ubiquitin transference
to the substrates associated with FHHt and other disorders.
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Leucine-rich repeat (LRR) proteins
LRR domains are composed of repeating 20–30 amino acid stretches that
are unusually rich in the hydrophobic amino acid leucine (Kobe & Deisenhofer,
1994). They are composed of tandem copies of LRR repeat (also known as α/β
horseshoe fold) that typically fold together to form a solenoid protein domain very
similar to the one observed in the WD40 domain-containing proteins. The LRR
repeat is present in many prokaryotic and eukaryotic proteins and is one of the
most commonly occurring protein domains in proteins associated with innate
immunity (Ng et al., 2011). Leucine-rich repeats are frequently involved in the
formation of protein-protein interactions, so might as well interact with Cul3 and/or
with its substrates.

WD40 domain-containing proteins
WD40 domains are β-propeller domains that act as protein interaction
scaffold in multiprotein complexes (Stirnimann et al., 2010). They are composed
of tandem copies of the WD40 repeat (also known as the WD or beta-transducin
repeat) that typically fold together to form a type of circular solenoid protein domain
(Xu & Min, 2011). They are among the most abundant identifiable protein domains
(Schapira et al., 2017). Found in a wide variety of eukaryotic proteins, WD40
domain-containing proteins perform functions such as adaptor/regulatory modules
in a diverse array of cellular processes (Xu & Min, 2011). Their ability to act as a
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scaffold platform for a stable or reversible association of binding partners may be
useful for the Cul3 complex assembling and/or interaction with its substrates.

Potential substrate adaptors for the Cul3 complex: In 2014, our group identified
a new set of Cul3-bound proteins that contained either the LRR or WD40 domains
and were known as CLWs (Wimuttisuk et al., 2014). We also demonstrated that
the LRR domain-containing proteins could bind both Cul3 and BTB domaincontaining proteins. This dual binding role for the LRRs causes the BTB-domain
protein to become a substrate instead of an adaptor. To our surprise, our MSbased proteomic study identified 32 WD40 domain-containing proteins and 9 LRR
domain-containing proteins (Table 3.8). At the initial stage of this data analysis, we
were inclined to designate these proteins as potential substrates for the Cul3based ubiquitin ligase complex. However, after a careful functional comparison,
we found some compelling evidence supporting the hypothesis that they may be
Cul3 substrate adaptors, not substrates. (1) As previously mentioned, we have
observed increased abundance of two Cul3 adaptors, Klhl3 and Keap1, in cells
lacking Cul3 (McCormick et al., 2014; Watai et al., 2007). (2) Besides the dual
binding role of LRR domain-containing proteins characterized by Wimuttisuk et al.,
crystal structures of other cullin complexes revealed that the WD40 and the LRR
domains are also common among F-box and DWD proteins, which serve as
substrate adaptors for the SCF (Skp1-Cul1-F-box) ubiquitin ligase complex and
the DDB1-Cul4A ubiquitin ligase complex. (Zheng et al., 2002; Angers et al.,
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2006a; He et al., 2006). Taken together, I propose an alternative model for the
WD40/LRR domain-containing proteins as novel substrate adaptors of the BCR
ubiquitin ligase complex, instead of investigating them as potential substrates.
Future biochemical analysis will be essential to define the cellular role of these two
subsets of proteins.

PROTEINS WITH SIGNIFICANT LOW SPECTRAL COUNTS IN CUL3 KO
CELLS
We have previously shown that Cul3 KO cells have elevated levels of
several known Cul3 substrates (McEvoy et al., 2007; Davidge et al., 2019).
Therefore, in order to identify candidate Cul3 targets and pathways that may
contribute to the initial renal injury observed in KS-CUL3 KO mice, we primarily
focused our analysis on the proteins with high spectral counts. However, I
observed that among the 3265 proteins identified in both cell lines, 317 had a fold
change ≤ -1.5, with 46 proteins showing a statistically significant difference
between WT and Cul3 KO cells (p-value ≤ 0.05). I hypothesize that this
phenomenon is caused by an enhancement in levels of intermediary proteins that
regulate the expression of the ones with reduced levels in Cul3 KO cells compared
to WT. These intermediary regulators are likely to be ubiquitinated by Cul3 and
targeted to degradation by the 26S proteasome. However, in Cul3 KO cells, they
can no longer be ubiquitinated, which leads to a rise in their cellular levels and,
consequently, a reduction in the levels of their target proteins (Figure 3.6). Further
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tests will be necessary to test this hypothesis and, hopefully, they will help to
expand our understanding of all the cellular pathways in which Cul3 is involved.

Validation of the proteomics data by immunoblot analysis: To validate the
proteomics data, we focused our attention on two proteins of interest, whose
spectral counts were altered and for which antibodies were available. These were
ubiquitin-conjugating enzyme D1 (UbE2D1) and Leucine-rich repeat 1 (LRR1). As
shown in Figure 3.7A, the levels of UbE2D1 undergo dramatic alteration in the KO
in comparison to the WT cells. The same applies to LRR, whose amount is lower
in the absence of Cul3 while being unaffected or even slightly increased in the WT
cells (Figure 3.7B). The variations observed in the Western blot analysis are in
accordance with the data obtained in the Mass Spectrometry analysis and reveal
a distinguishable effect on the proteome of KO compared to the WT cells.

DISCUSSION
The discovery of Cul3 launched a rapidly expanding research niche that had
a strong potential to affect clinical practice. The characterization of this E3 ligase
has evolved quickly and resulted in the identification of a variety of substrates and
members of the BCR complex (Xu et al., 2003; Pintard et al., 2004; Dubiel et al.,
2017). Yet, there is still much to be discovered to fully understand the nature of
Cul3 protein. In the work presented here, MS-based proteomics identified novel
components of the Cul3 complex and possible pathways of Cul3 interactions. I
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categorized potential members of the Cul3 complex using three different
approaches: (1) classification of potential Cul3-binding partners based on their
molecular function and class, (2) identification of potential substrates and cellular
processes, and (3) determination of the conserved domains of the proteins with
high spectral counts and their roles in the Cul3-based ubiquitin ligase complex.
Here, I discuss the significance of my findings, present an alternative BCR complex
model based on the analysis of conserved domains, and consider future studies
that may arise from this MS-based proteomics experiment.

Pathways in which Cul3 is involved: Prior studies have identified multiple
abnormalities in cells that lack Cul3 (Genschik et al., 2013; Dong et al., 2020;
Cornelius et al., 2018). Here, I have extended these past approaches and
demonstrated more defined alterations of multiple cytoskeletal, translational, and
developmental proteins in Cul3 KO cells (Figure 3.4). Changes in the three protein
categories are consistent with the reported biology of Cul3 (Figure 3.5A and 3.5B).
For example, Cul3 was shown to mediate the transport and biogenesis of vesicles
in the Golgi apparatus, the secretion and concentration of large cargo in the ER,
and the synthesis of IPs in the ER lumen (McGourty et al., 2016; Jin et al., 2012;
Saito & Katada, 2015; Kim et al., 2018; Bisnett et al., 2021). Similarly, Cul3 was
also shown to regulate the levels of proteins involved in DNA damage response
and repair, cell proliferation, and development of malignancies (Ribar et al., 2007;
Sun et al., 2016; Vanneste et al., 2020). Overall, the broad range of proteins that
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were differentially regulated in my proteomics analysis confirmed that endogenous
Cul3 is associated with several signaling pathways and affects proteins in three
major categories.

Role of Cul3 in Familial Hyperkalemic Hypertension: Arterial hypertension is
the number one risk factor for death worldwide (Narayan et al., 2010), with a
prevalence ranging between 30 and 40% in the adult population. Familial
hyperkalemic hypertension (FHHt), also known as Gordon syndrome or
pseudohypoaldosteronism type II, is a rare inherited hypertension syndrome
(McCormick et al., 2014). It is characterized by severe arterial hypertension,
hyperkalemia, hyperchloremic metabolic acidosis, hypercalciuria, and low renin
state. Cul3, Klhl3, Wnk1, and Wnk4 are named as the four foes causing FHHt. A
remarkable body of work aimed at understanding how the product of these genes
modulates ion transport in the distal part of the nephron and, thus, causes
hypertensive manifestations (Farfel et al., 2019). Mutations in Klhl3 produce a
dominant or recessive form of FHHt (Boyden et al., 2012; Louis-Dit-Picard et al.,
2012), and mutations in Cul3 are associated with an increased severity of FHHt
(Boyden et al., 2012). The Cul3-Klhl3 complex recruits the WNK kinases for
ubiquitination to promote their proteasomal degradation. Mutations in Klhl3 disrupt
the interaction with the substrates or Cul3, thus preventing the degradation of
WNKs (McCormick et al, 2014). Mutations in Cul3 also abrogate WNK
ubiquitination, but the effect is indirect, via increased ubiquitination and
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degradation of KLHL3 (Ohta et al., 2013). Besides Klhl3, Wnk1, and Wnk4, several
other proteins have shown to be affected by mutations of Cul3 and, consequently,
are also involved in the development of FHHt. Our functional analysis has revealed
that Wnk1, RhoA, and RhoB were upregulated in the KO cells, which is in
accordance with the results described in the literature (Terker et al., 2018;
Cornelius et al., 2018; Chen et al., 2009; Murakami et al., 2019;). In addition, our
analysis has also identified four other proteins that were upregulated in the KO
cells and play specific physiological roles in the kidney. Even though they have not
been characterized as Cul3 substrates yet, ERK1 and ERK2 have the potential to
be ubiquitinated by Cul3 and, possibly, be involved in the severe phenotype of
FHHt.

Model of the novel BCRWD40/LRR complex: A conserved domain analysis revealed
domains that are frequently found in proteins that interact with Cul3. In particular,
we observed that proteins containing the WD40 and the LRR domains are present
more often in the wild type than in the knockout cells. Initially, we hypothesized
that these proteins represented groups of substrates that were recognized by the
Cul3 complex via their conserved domains. However, a structural analysis
revealed that the WD40 and the LRR domains were the substrate adaptor domains
of the F-box proteins in the Cul1-based ubiquitin ligase complex (Schulman et al.,
2000; Zheng et al., 2002). Furthermore, the similarity between the Skp1 and BTB
domains also suggests that the binding between BTB domain-containing proteins
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and WD40/LRR domain-containing proteins may be similar to the binding
interaction between the Skp1 and F-box proteins (Pintard et al., 2004).
Additionally, a study using MudPIT analysis of the Cul4A-based ubiquitin ligase
complex has identified clusters of WD40 domain-containing proteins that were later
shown to be substrate adaptors for the Cul4A complex (Angers et al., 2006a; He
et al., 2006). Therefore, I propose that the WD40/LRR domain-containing proteins
are likely to be substrate adaptors for the Cul3 complex, not substrates.

Future studies: In conclusion, our MS-based proteomic analysis revealed
a substantial amount of information that can be used to characterize the Cul3based E3 ligase complex in future experiments. First, I have identified two potential
Cul3 substrates involved in FHHt and two involved in cancer. Second, I have found
clusters of proteins that contain UPS, UBC fold, WD40 or LRR domains, which
suggests they may be used for protein-protein interaction with Cul3, its substrate
adaptors, or its substrates. Third, I proposed that these WD40 and LRR proteins
are likely to serve as additional substrate adaptor modules for the Cul3-based
ubiquitin ligase complex when their BTB domain-containing proteins cannot recruit
substrates due to the absence of a second protein-protein interacting domain.
Although additional biochemical experiments are required to confirm the proposed
models, future characterization of the Cul3 complex based on these hypotheses
will lead to a more thorough understanding of the ubiquitination mechanism of the
Cul3-based ubiquitin ligase complex and its correlation to other cellular processes.
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MATERIALS AND METHODS
Cell culture and transfections: Cells (HEK293 wild type and Cul3 knockout) were
maintained in DMEM (Gibco™, CAT no. 11965092) supplemented with 10% Fetal
Bovine Serum (Atlas Biological, CAT no. F-0500-A), 1% L-Glutamine (Gibco™,
CAT no. 25030081), and 1% Penicillin/Streptomycin (Gibco™, CAT no.
15070063). Cells were split 1:20 for transfection in 6 cm dishes the night before
transfection. Transfections were performed using the calcium phosphate
precipitation (Jordan et al., 1996). For immunoprecipitations and Western blots,
cells were harvested 48 hours post-transfection. The amount of plasmid DNA
transfected into each plate varied from 1 to 10μg. All transfected cells were
scrapped and harvested using 600μL of a solution containing 10mL of
radioimmunoprecipitation assay lysis buffer (RIPA) mixed with 1 protease inhibitor
tablet (Thermo Scientific™, CAT no. PIA32953), and then sonicated with an
ultrasonic cell disrupter (VIRTIS VIRSONIC 100) for 15 seconds at 50% power
before being used for immunoprecipitations or western blots. CRISPR knockout
Cul3 HEK293 cells were a gift from Curt Sigmund.
Western

blotting

and

immunoprecipitations:

Western

blots

and

immunoprecipitations were conducted as previously described (Wimuttisuk et al.,
2014). In short, 500μL of the sonicated transfection lysate was added to the
desired antibody in a microcentrifuge tube. 40 μl of RIPA–Sepharose beads
(Thermo Scientific™, CAT no. 101041) were then added to the mixture, and the
immunoprecipitations were placed on a rotator for 2 h at room temperature before
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being rinsed with RIPA buffer for 15 seconds at 1500rpm, heated in 15μL of SDSPAGE loading buffer for 2 minutes, and ran on an SDS-PAGE gel. The following
antibodies were used for immunoprecipitations at 1–2 μg or at the indicated dilution
for western blotting: polyclonal anti-HA (1:1000, CAT no. PA1-985, Invitrogen™),
polyclonal anti-β actin (CAT no. AM4302, Invitrogen™), polyclonal anti-Cul3
(Singer et al., 1999; McEvoy et al., 2007), and monoclonal anti-cyclin E (HE12)
(1:100 for transfected samples, CAT no. 32-160-0, Invitrogen™), Goat anti-Rabbit
IgG (H+L) Secondary Antibody, HRP (1:10000 for transfected samples, CAT no.
31460, Invitrogen™), Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary
Antibody, HRP (1:10000 for transfected samples, CAT no. G-21040, Invitrogen™).
Western blots were visualized using myECL™ Imager (CAT no. 62236, Thermo
Scientific™).
Peptide preparation, desalting, and reconstitution: Cell lysates were collected
as described above, and their protein concentrations were measured with a BCA
assay (CAT no. 23225, Thermo Scientific™). Extracted proteins were reduced with
45 mM DTT at 60 °C for 20 min, and alkylated with 100 mM IAA in the dark at room
temperature for 15 min. The proteins were digested with trypsin (Promega, CAT
no. V5111) at a ratio of 1:50 (trypsin/protein w/w) at 37 °C overnight. Digested
peptides were desalted with a SepPak C18 cartridge (Waters, CAT no.
WAT051910), kept in −80 °C for 1h, and dried in a lyophilizer for 48h. Then, the
digested peptides were stored at −80°C. Dry peptides were centrifuged for 5 min
at room temperature and resuspended in 0.9X of the total volume using 0.1M
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acetic acid. The peptide suspensions were briefly centrifuged to collect the
resuspensions at the bottom of the tubes then transferred clear 1.5 mL tubes. The
samples were centrifuged at 13000x for 5 min at room temperature, and 9uL of
peptide supernatant was added to new tubes containing 1uL or peptide standards.
The tubes were sealed and briefly centrifuged to remove bubbles and collect the
samples at the tubes' bottom.
Automated MS-based label-free proteomics analysis: The mass spectrometry
and protein sequence prediction were performed by a collaborator from the
Salomon lab - Brown University.
Data analysis and peptide quantification: Data analysis was primarily
performed using GraphPad Prism 9, MaxQuant, and Microsoft Excel. The
differences between the two groups were analyzed with a two-tailed Students ttest.
Gene Ontology (GO) enrichment analysis: The PANTHER version 15.9 Online
Tool was used to perform a functional GO enrichment analysis on the two
proteomics datasets, WT and Cul3 KO. Step 1: the UniProt IDs of the proteins with
significant high or low spectral counts were entered in the Panther software
interface for a comparison to its reference ID list. Step 2: the organism selected for
comparison was Homo sapiens. Step 3: the analysis selected was “Functional
classification viewed in graphic charts” followed by the selection of the option was
“Pie-charts”.
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REACTOME analysis: The “Analyze gene list” was the Reactome tool chosen for
this study. Step 1: the UniProt IDs of the proteins with significant high or low
spectral counts were entered in the Reactome software interface for a comparison
to its reference ID list. Step 2: the preferred option selected was “Include
interactors”. Step 3: the visualization mode selected was “Voronoi”.
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Figure 3.1 – Validation and characterization of Cul3 KO cells: A) Cellular lysates of two
replicates of wild type (WT) and two replicates of CUL3 knockout (KO) clones were analyzed by
western blot with the indicated antibodies. Actin is the loading control. B) Comparison of cyclin E
expression levels between WT and KO clones. C) WT cells and KO clones were treated with
cycloheximide (CHX) for 12h, and cyclin E half-life was determined. Actin is the loading control.
This experiment was repeated three times and yielded similar results.

129

Table 3.1 - Reproducibility of LC-MS/MS results: Number of proteins observed in four WT and

Table 1 – Reproducibility of LC-MS/MS results from four WT and four Cul3(-/-)
four biological
Cul3(-/-) biological
replicates.
replicates

Biological
Replicate

WT 1

WT 2

WT 3

WT 4

KO 1

KO 2

KO 3

KO 4

Number of
Proteins

2869

2875

2847

2737

2896

3018

2687

2532

Average ± SD

2832 ± 56

P-value

2783 ± 187
0.9178

Biological Replicates: Four biological replicates of WT and KO cell lines were used in the LCMS/MS analysis. The replicates referred in this work are biological replicates, not analytical or
technical replicates of a single biological sample.
Proteins: The relative amount of a specific protein was calculated using the number of observed
spectral count of the specific protein and the internal standards.

Statistical Analysis: Student t-test was used to compare the number of unique peptides identified
in the four WT replicates and four KO replicates. The t-test was performed with two-tailed in which
the number of proteins of the four WT replicates were compared to the number of proteins of the
four KO replicates. The hypothesis was that there were significant differences between the
replicates and statistically this was refuted (p-value of 0.9178).
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Table 3.2 - Reproducibility of LC-MS/MS results: Number of unique peptides observed in four

Table 2 – Reproducibility
of LC-MS/MS
results from
four .WT and four Cul3(-/-)
WT and four
Cul3(-/-) biological
replicates
biological replicates
Biological
Replicate

WT 1

Number of
Unique
Peptides

13748 14007 13479 12279 14400 14878 13420 11203

Average ± SD

WT 2

WT 3

WT 4

KO 1

13378 ± 662

P-value

KO 2

KO 3

KO 4

13475 ± 1413
0.6807

Biological Replicates: Four biological replicates of WT and KO cell lines were used in the LCMS/MS analysis. The replicates referred in this work are biological replicates, not analytical or
technical replicates of a single biological sample.
Unique Peptides: A unique peptide is defined as a peptide, irrespective of its length, that exists
only in one protein of a proteome of interest, even though this peptide may appear more than once
in the same protein.

Statistical Analysis: Student t-test was used to compare the number of unique peptides identified
in the four WT replicates and four KO replicates. The t-test was performed with two-tailed in which
the number of unique peptides of the four WT replicates were compared to the number of unique
peptides of the four KO replicates. The hypothesis was that there were significant differences
between the replicates and statistically this was refuted (p-value of 0.6807).
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Figure 3.2 – Workflow of the mass spectrometry-based label-free quantitative proteomics:
WT and KO samples were subjected to individual LC-MS/MS analysis and the quantification was
based on the comparison of peak intensity of the same peptide or the spectral count of the same
protein.
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Figure 3.3 – Proteomic analysis of WT and KO cells: (A)Summary of the results observed in the
LC-MS/MS proteomics analysis. (B)Volcano plot of the 4087 proteins quantified in the four WT and
four Cul3(-/-) replicates. (C) KO/WT ratio of the proteins that a significant difference in their spectral
counts. WT refers to wild type, and KO refers to Cul3 knockout replicates.
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Figure 3.4 – Functional analysis of proteins with significant high and low spectral counts in

Cul3 KO cells: (A) PANTHER (Protein ANalysis THrough Evolutionary Relationships) of

statistically significant downregulated and (B) upregulated proteins in CUL3 KO cells.
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Figure 3.5 - REACTOME pathway analysis of proteins whose spectral counts were
significantly different (+/−50%): Figures (A) Upregulated and (B) Downregulated show a
genome-wide overview of the results of the REACTOME pathway analysis. REACTOME
pathways are arrange by hierarchy. The color code denotes over-representation of that pathway
in the input dataset. Light gray signifies pathways which are not significantly over-represented.
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Table 3.3 – The 25 most relevant pathways that are upregulated in Cul3(-/-) cells sorted by
p-value. FDR refers to False Discovery Rate. (Source: REACTOME).
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Table 3.4– The 25 most relevant pathways that are downregulated in Cul3(-/-) cells sorted
by p-value. FDR refers to False Discovery Rate. (Source: REACTOME).
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proteins and C ul3, fourth column s hows the clinical implications of the protein, and fifth column s hows the most recent

proteins , s econd column s hows their fold changes , third column s hows how the molecular connection between the

been characteriz ed as C ul3 targets were identified in our MS analys is . F irst column s hows the name and gene of the

T able 3.6 – C linic al implic ations of potential C ul3 s ubs trates involved in F HHt: F our kidney proteins that have not
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fourth column s hows the most recent reference des cribing the protein roles .

of the proteins , s econd column s hows their cellular roles , third column s hows the clinical implications of the protein, and

have not been characteriz ed as C ul3 targets were identified in our MS analys is . F irst column s hows the name and gene

T able 3.7 – C linic al implic ations of potential C ul3 s ubs trates not involved in F HHt: T wo tumor s uppres s ors that

Table 3.8 – Summary of proteins that contain conserved domains of interest from MS-based
proteomic analysis. First column shows the different domains observed among the altered
proteins, second column shows the protein names, and third column shows their UniProt©
accession number (The UniProt Consortium, 2021)

Domains

WD40

WD40 and HMG-box
WD40 and FYVE
WD40 and PI

UPS

UBC fold

RasGAP
Kelch

Kinase

Protein name
WD repeat protein BING4
WD repeat protein 4
WD repeat protein 1
WD repeat endosomal protein
WD repeat domain 82
WD repeat domain 79
WD repeat domain 76
WD repeat domain 75
WD repeat domain 74
WD repeat domain 68
WD repeat domain 6
WD repeat domain 50
WD repeat domain 5
WD repeat domain 47
WD repeat domain 44
WD repeat domain 39
WD repeat domain 36
WD repeat domain 33
WD repeat domain 3
WD repeat domain 26
WD repeat domain 21B
WD repeat domain 18
WD repeat domain 12
Glutamate rich WD repeat containing 1
Coronin 1B
Coronin 7
Coronin 2A
Coronin 1C
Coronin 1A
WD repeat and HMG box DNA binding protein 1
WD repeat and FYVE domain containing 1
Peptidylprolyl isomerase domain and WD repeat containing 1
Ubiquitin specific protease 5
Ubiquitin specific protease 6
Ubiquitin specific protease 7
Ubiquitin specific protease 10
Ubiquitin specific protease 11
Ubiquitin specific protease 14
Ubiquitin specific protease 15
Ubiquitin specific protease 19
Ubiquitin specific protease 24
Ubiquitin specific protease 24
Ubiquitin specific protease 36
Ubiquitin specific protease 39
Ubiquitin specific protease 45
Ubiquitin specific protease 47
Ubiquitin conjugating enzyme
Ubiquitin conjugating enzyme
Ubiquitin conjugating enzyme
Ubiquitin conjugating enzyme
Ubiquitin conjugating enzyme
Ubiquitin conjugating enzyme
Ubiquitin conjugating enzyme
Ubiquitin conjugating enzyme
Ubiquitin conjugating enzyme
Ubiquitin conjugating enzyme
Ubiquitin conjugating enzyme
Ubiquitin conjugating enzyme
Ubiquitin conjugating enzyme
Ubiquitin conjugating enzyme
Ubiquitin conjugating enzyme
RhoA
RhoB
Kelch-like 7
Cyclin dependent kinase 2
Cyclin dependent kinase 4
Cyclin dependent kinase 5
Cyclin dependent kinase 7
Cyclin dependent kinase 9

E2 variant 1
E2 variant 2
E2-25K
E2A
E2C
E2D1
E2D2
E2E 2
E2E1
E2E3
E2I
E2L3
E2M
E2N
E2S

Accession #
O15213
P57081
O75083
Q8TAF3
Q6UXN9
E9PMR3
A0A0C4DFX7
Q8IWA0
E9PS41
P61962
A0A087X295
Q9Y5J1
P61964
A0A0A0MRE6
Q5JSH3
O76071
A0A0A0MTB8
Q9C0J8
Q9UNX4
Q9H7D7
Q3SXM0
K7EIR0
Q9GZL7
Q9BQ67
Q9BR76
A0A0A6YYL4
Q92828
B4E3S0
P31146
O75717
Q8IWB7
F5H7P7
P45974
P35125
F5H2X1
Q14694
G5E9A6
P54578
Q9Y4E8
B5MEG5
Q9UPU5
Q9UPU5
A0A075B784
A0A087X1B2
E2QRF0
Q96K76
I3L0A0
G3V113
P61086
A0A0D9SEZ6
O00762
A0A087WW00
A0A087WY85
F8W8F0
A0A087X283
Q969T4
B0QYN7
P68036
P61081
F8VQQ8
Q16763
P61586
C9JRM1
Q8IXQ5
G3V5T9
Q96BE9
Q00535
D6R9G1
P50750
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UPS

UBC fold

RasGAP
Kelch

LRR
Kinase

Ubiquitin
Ubiquitin
Ubiquitin
Ubiquitin
Ubiquitin
Ubiquitin
Ubiquitin
Ubiquitin
Ubiquitin

specific
specific
specific
specific
specific
specific
specific
specific
specific

protease
protease
protease
protease
protease
protease
protease
protease
protease

14
15
19
24
24
36
39
45
47

Ubiquitin conjugating enzyme E2 variant 1
Ubiquitin conjugating enzyme E2 variant 2
Ubiquitin conjugating enzyme E2-25K
Ubiquitin conjugating enzyme E2A
Ubiquitin conjugating enzyme E2C
Ubiquitin conjugating enzyme E2D1
Ubiquitin conjugating enzyme E2D2
Ubiquitin conjugating enzyme E2E 2
Ubiquitin conjugating enzyme E2E1
Ubiquitin conjugating enzyme E2E3
Ubiquitin conjugating enzyme E2I
Ubiquitin conjugating enzyme E2L3
Ubiquitin conjugating enzyme E2M
Ubiquitin conjugating enzyme E2N
Ubiquitin conjugating enzyme E2S
Leucine rich PPR motif containing protein
RhoA
RhoB
Leucine rich repeat containing 1
Leucine rich
Kelch-like
7 repeat containing 16
Leucine
rich repeat
containing
40
Cyclin
dependent
kinase
2
Leucine
rich repeat
containing
47
Cyclin
dependent
kinase
4
Leucine
rich repeat
containing
49
Cyclin
dependent
kinase
5
Leucine
rich repeat
containing
57
Cyclin
dependent
kinase
7
Leucine
rich repeat
containing
59
Cyclin
dependent
kinase
9
Leucine rich repeat in FLII interacting protein 1

P54578
Q9Y4E8
B5MEG5
Q9UPU5
Q9UPU5
A0A075B784
A0A087X1B2
E2QRF0
Q96K76
I3L0A0
G3V113
P61086
A0A0D9SEZ6
O00762
A0A087WW00
A0A087WY85
F8W8F0
A0A087X283
Q969T4
B0QYN7
P68036
P61081
F8VQQ8
Q16763
A0A0C4DG06
P61586
C9JRM1
A0A0G2JNZ2
Q5VZK9
Q8IXQ5
Q9H9A6
G3V5T9
Q8N1G4
Q96BE9
H0YKE9
Q00535
Q8N9N7
D6R9G1
Q96AG4
P50750
Q32MZ4
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Cul3
No ubiquitination
by Cul3

Increased
levels

Decreased
levels

Intermediary
protein

Target
protein
Enhancement in
degradation

No degradation
by the 26S
proteasome

Figure 3.6 – Proposed mechanisms of control for the proteins with low spectral counts: In
Cul3 KO cells, intermediary regulators are likely to be ubiquitinated by Cul3 and targeted to
degradation by the 26S proteasome. However, in Cul3 KO cells, they can no longer be
ubiquitinated, which leads to a rise in their cellular levels and, consequently, a reduction in the
levels of their target proteins
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B
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2
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1
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HA-UbE2D1

+

+

HA-LRR1

+

+

KO

WT

KO

WT

WB: Cul3

WB: Cul3

WB: HA-UbE2D1

WB: HA-LRR1

WB: Actin

WB: Actin

Quantification
of UbE2D1 (%)

100%
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Quantification
of LRR1 (%)

100% 150%

Figure 3.7 – Validation of the proteomics analysis: HEK 293 WT and Cul3 KO cells were cotransfected with HA-UbE2D1 or HA-LRR1. Immunoblotting was used to probe for endogenous Cul3
(first rows), HA-UbE2D1 and HA-LRR1 (second rows), control Actin (third rows), and quantification
of the western blot bands (fourth rows). (A) Protein with high spectral count: expression levels of
UbE2D1 in KO and WT cells. (B) Protein with low spectral count: expression levels of LRR1 in KO
and WT cells.
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DISCUSSION
This dissertation focuses on the structure and function of a ubiquitin E3
ligase. Chapter 2 describes a series of experiments focusing on a hypothesis that
the protein that helps the complex identify substrates may also participate in the
selection of the E2 enzyme. Chapter 3 describes a proteomics approach to testing
the hypothesis that Cul3 regulates yet unidentified additional substrates in kidney
cells. Below, I will discuss different regulatory mechanisms involved in the function
of the Cul3 complex, the significance of our findings, and the relationship between
the two approaches taken to characterize the Cul3-based ubiquitin ligase. Lastly,
we will also propose future experiments to continue the thorough characterization
of the mammalian Cul3 complex and support its relevance at the cellular and
organismal levels.

THE POTENTIAL ROLE OF CUL3 ADAPTORS IN E2 SELECTION
The chemistry behind the conjugation of ubiquitin to its substrate has been
rigorously studied, but the mechanism of E2 recruitment and polyubiquitin chain
formation has not yet been elucidated (Hochstrasser, 2006). The majority of the
information regarding these processes comes from finding out that the binding site
of the ubiquitin-activating enzyme and the ubiquitin ligase overlap on the surface
of the ubiquitin-conjugating enzyme. In addition, the order in which the ubiquitin
molecule can be transferred in the ubiquitination pathway is limited because the
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ubiquitin-conjugating enzyme cannot bind the ubiquitin-activating enzyme and the
ubiquitin ligase simultaneously. (Eletr et al., 2005; Kleiger et al., 2009).
Several hypotheses have been raised to explain the mechanisms of E2
recruitment and substrate ubiquitination (Hochstrasser, 2006). The most popular
one is the traditional sequential model that proposes that the ubiquitin molecules
are transferred from an E1 enzyme to an E2 enzyme that binds to Cul3. Then,
together, they transfer the ubiquitin to the substrate. (Figure 4.1A). Several studies
have also indicated that the recruitment of the E2 is entirely random and occurs
independently of the substrate that is being ubiquitinated. In addition, models have
suggested that the recruitment of E2s for the ubiquitin-conjugation process occurs
independently of the substrate that is being ubiquitinated and involves the Cterminus of Cul3 interacting with the ubiquitin-conjugating enzyme (E2) and the Nterminus interacting with and recruiting the substrate via a BTB domain-containing
protein (Figure 4.1A).
In the study presented here, I have made three important observations
about this subject. First, I determined that Cul1 and Cul3 have differential binding
preferences for E2s. Second, I determined that the N-terminus region of Cul3
contained the E2 binding specificity of the wild-type Cul3. Third, a BTB adaptor
protein is required for this interaction to occur, which implies that the BTB domaincontaining proteins are likely to be involved in the E2 recruitment and certain E2
enzymes can interact with both termini of Cul3 (Figure 4.1B).
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Undoubtedly, these results provide strong evidence supporting the
hypothesis that BTB domain-containing proteins participate in the E2 selection
process. However, many questions remain unanswered regarding this novel
mechanistic insight, including:
(1) Does the Cul3 complex always utilize this mechanism to choose E2s?
(2) What part of the BTB domain-containing protein is involved in this novel
E2-BTB domain-containing protein interaction?
(3) What part of the E2 protein is involved in binding the BTB domaincontaining protein?
(4) What, if any, role does the previously characterized Rbx1 recruitment
play in E2 selection?

These questions center around three main protein families: BTB domaincontaining proteins, ubiquitin-conjugating enzymes (E2s), and Cullins. As
discussed in the introduction, we know a lot about the functional domains of each
of these families. In the following sections, I will discuss their classes, structures,
and functional domains, consider the implications of each question, and suggest
strategies on how to address them.

I.

BTB domain-containing proteins

The BTB domain-containing protein gene family is characterized by the
presence of one or more BTB domains in each family member and is found widely
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in eukaryotes (Zollman et al., 1994). The human genome encodes 188 BTB
proteins that can be divided into subfamilies according to the presence or absence
of additional domains, including BTB only proteins, BTB-ZF proteins, BTB-Kelch
proteins, BTB-BACK proteins, BTB-BACK-Kelch proteins, MATH-BTB proteins,
BTB-ANK proteins, BTB-BACK-PHR proteins, and Rho-BTB proteins (Figure 4.2;
Stogios et al., 2005; Li et al., 1999). As mentioned in chapter 1, they function as
substrate adaptors during protein ubiquitination by the Cul3 complex. In these
proteins, the BTB domain is proposed to interact with Cul3, whereas the second
domain, such as the ZF, Kelch, ANK, or MATH domain, is presumed to act as the
substrate-recognition module (Boeckmann et al., 2004).
Despite the vast diversity, there are not many known BTB domaincontaining proteins capable of interacting with ubiquitin-conjugating enzymes. In
chapter 2, we demonstrated that RhoBTB3 could interact with UbE2E1, but
besides this result, only a BTB-BACK-Kelch family member has been shown to
bind to an E2. The structure and functional domains of these two BTBs vary
drastically, suggesting that they are likely using distinct domains to interact with
the E2s. Regarding the BTB-BACK-Kelch protein, its recently identified BACK
domain has not yet a defined function (Stogios & Prive, 2004). We hypothesize
that it may be a vital component for the protein-protein interaction with the E2. To
test this, we can delete it from the BTB-BACK-Kelch protein and examine the
binding to the E2. Regarding the domain that RhoBTB3 uses to interact with
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UbE2E1, we have available a unique set of mutants that can be used in further
binding tests.

II.

Ubiquitin-conjugating enzymes (E2s)

As described in Chapter 1, much is known about their structure and functional
domains. In the human genome, there are 35 E2s exclusively dedicated to
ubiquitin conjugation. They are grouped according to the presence of appendages
either N- or C-terminus to the catalytic domain (Classes II and III, respectively), at
neither (Class I), or at both ends (Class IV). They all share a ~150-amino acid
conserved catalytic core domain, known as the ubiquitin conjugation (UBC)
domain, which is the minimal sufficient unit for the E2 enzymatic activity. We
hypothesize that their appendages may be involved in the binding interaction with
BTB domain-containing proteins. To test this, we can delete them from UbE2E1
and test for changes in binding to RhoBTB3. We can also use the fact that we have
several related E2s, some of which bind and many that do not to do an alignment,
to attempt to identify unique sequences found in common with binders.

III.

Cullins

As described in chapter 2, we developed cullin chimeras in which we fused the
N- or C-terminus of Cul1 to the N- or C-terminus of Cul3 (Figure 2.1). We can take
advantage of this unique set of tools to characterize the role of Cullins domains in
the interaction with E2s and, possibly, expand our knowledge on this novel
172

selection mechanism. A crucial question that needs to be addressed is what, if
any, role does the previously characterized Rbx1 recruitment play in E2 selection?
We have the tools to examine this question, a mutant that does not bind Rbx1 was
created and characterized in our laboratory and would be an invaluable tool for
such an analysis (Wimuttisuk & Singer, 2007). Another critical question that needs
to be answered is what region of the N-terminus Cul3 is responsible for the
interaction with the E2s? Besides the mutant that cannot bind to Rbx1, we have at
our disposal a variety of other mutants with specific deletions that would be very
helpful in pinpointing the binding region.

POTENTIAL

PATHWAYS

OF

CUL3

INTERACTIONS

AND

NOVEL

COMPONENTS OF THE CUL3 COMPLEX
Since its discovery, Cul3 has emerged as a critical player in recognizing and
recruiting numerous important substrates for ubiquitination. The heterogeneity of
substrates, substrates adaptors, intracellular and intercellular processes in which
Cul3 is involved demonstrates this E3 ligase's relevance at both the cellular and
organismal level. Although progress has been awe-inspiring over the past
decades, there is still much that remains to be discovered to understand this
intriguing class of Cullin-RING ubiquitin ligases fully. In the following sections, I
examine the cellular effects of Cul3 dysregulation as well as how this can lead to
the development of several disorders. In addition, I discuss the role of Cul3 in cell
signaling and propose a novel model for the BCR complex.
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I.

Correlations between Cul3 substrates and diseases

The characterization of the Cul3 complex provides a better understanding
of the ubiquitination process and may also offer preventative strategies and
treatments for diseases caused by any disruptions in the Cul3 gene and
misregulation of its substrates. Our first chapter demonstrated the importance of
the Cul3-based ubiquitin ligase by providing a short description of Cul3 target
proteins and describing some of the Cul3 roles in different diseases. For example,
accumulation of cyclin E, a well-known Cul3 substrate, could lead to breast,
ovarian, and colon cancers (Buckley et al., 1993; Guardavaccaro and Pagano,
2004; Hunt and Keyomarsi, 2005; Rosen et al., 2006). In addition, misregulation
of the transcription factor Nrf2, which is a multi-organ protector against oxidative
stress response, has been linked to the onset of several diseases, including
carcinomas, Parkinson's disease, and lupus autoimmune disease (Yoh et al.,
2001; Yu and Kensler, 2005; Burton et al., 2006; Hayes and McMahon, 2006).
Overexpression of WNK1 and WNK4, which regulate the activity of the
major sodium and potassium transporters in the distal nephron (NCC), is the
leading cause of hypertension and hyperkalemia symptoms observed in patients
with Familial hyperkalemic hypertension (FHHt; McCormick et al., 2014; Cornelius
et al., 2018). Furthermore, failure to ubiquitinate Cul3 substrates involved in Xchromosome inactivation may lead to male-lethal X-linked traits, such as focaldermal hypoplasia and oral-facial-digital syndrome type 1 (Franco and Ballabio,
174

2006; Happle, 2006). These substrates include H2AFY and possibly a novel Cul3binding protein named RBM10. Additionally, two potential Cul3 substrates
identified in our MS-based proteomic analysis, known as ERK1 and ERK2, are
likely to play crucial roles in their cellular pathways as well as in the developmental
process of FHHt. Therefore, the characterization of the Cul3-based ubiquitin ligase
will contribute to a greater understanding of the underlying cause and potential
treatments of diseases stemming from the misregulation of the Cul3-based
ubiquitin ligase complex.

II.

Role of Cul3 in cell signaling

The E3 ubiquitin-protein ligase RSP5 catalyzes the mono-, di-, and multiubiquitination of different substrates that serve as signals for various cellular
pathways, including the 26S proteasome, endocytosis, and DNA repair (Galan and
Haguenauer-Tsapis, 1997; Huibregtse et al., 1997; Dunn and Hicke, 2001; Hicke,
2001). Contrastingly, the most prominent role of Cul3-based E3 ligase is to
ubiquitinate and target substrates for degradation by the 26S proteasome.
However, a growing body of research has shown that Cul3 can catalyze the
assembling of different ubiquitin linkages that serve as unique signaling molecules
not just for the 26S proteasome pathway but also for non-proteolytic signaling
processes (Jerabkova & Sumara, 2019; Maerki et al., 2009; Sumara & Peter, 2007;
Bade et al., 2014). Furthermore, Cul3 has been shown to catalyze the formation
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of polyubiquitin chains as well as the catalyzation of monoubiquitin attachments
(Hernandez-Munoz et al., 2007; Sumara et al., 2007).
Multiple well-known Cul3 substrates have been identified in our analysis
(Chapter 3). Most of them are known to be polyubiquitinated by Cul3 in the lysine
48 and targeted for degradation by the 26S proteasome. However, a subset of
substrates known to be either monoubiquitinated or polyubiquitinated in a different
lysine was also identified, revealing that the absence of Cul3 has more cellular
implications than just the overexpression of unwanted substrates. Besides the
proteasome pathway, DNA synthesis and repair, development, vesicle transport,
and cytoskeletal remodeling were some of the signaling processes disrupted in our
Cul3 KO cells (Table 4.1). To further understand the ubiquitination via Cul3, the
process of lysine selection, and the assembly of ubiquitin linkages, we will explore
possible mechanisms for substrate recognition and the signaling events required
to activate the Cul3-based ubiquitin ligase complex.

III.

WD40/LRR domain-containing proteins function as substrate
adaptors for Cul3

Identifying common conserved motifs in our MS-based proteomic analysis
revealed a subset of proteins that contained either WD40 or LRR domains
(Chapter 3). At first, we were inclined to categorize these proteins as potential
substrates for the Cul3-based ubiquitin ligase complex. However, a study
conducted by our group in which we found a new set of Cul3-bound proteins that
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contained either the LRR or WD40 domain made us reconsider our hypothesis. In
addition, they also demonstrated that these LRR domain-containing proteins could
bind both Cul3 and BTB domain-containing proteins, and this dual binding role for
the LRRs caused the BTB-domain protein to become a substrate instead of an
adaptor (Wimuttisuk et al., 2014). Furthermore, these domains are commonly
found as part of the F-box and DWD proteins, which serve as substrate adaptors
for the SCF (Skp1-Cul1-F-box) ubiquitin ligase complex and the DDB1-Cul4A
ubiquitin ligase complex, respectively (Zheng et al., 2002; Angers et al., 2006a; He
et al., 2006), and a current model of the BCR ubiquitin ligase proposes that the
BTB domain-containing protein recruits its substrate using a second proteinprotein interacting domain, such as a Kelch or a MATH domain. Thus, we proposed
that Cul3 may acquire an additional substrate specificity module by binding to
WD40/LRR domain-containing proteins, and they then serve as F-box-like
substrate adaptors for the complex.

IV.

Potential substrates involved in the severe phenotype of FHHt
Familial Hyperkalemic Hypertension (FHHt)

As discussed in chapter 3, FHHt is an inherited disorder manifested by
hyperkalemia and hypertension caused by the hyperactivation of the NCCs that
are expressed exclusively in the DCTs (Mayan et al., 2002; Isobe et al., 2012). For
the past two decades, considerable efforts have been taken to identify the proteins
involved in FHHt, which revealed that mutations in CUL3, its substrate adaptor
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KLHL3 and its substrates WNK1 and WNK4 can also lead to FHHt, with CUL3
knockouts causing the most severe form of FHHt. The phenotypic severity of Cul3
knockouts compared to the phenotypes observed in the other three proteins
suggests that other contributing factors besides Klhl3-Wnk1/Wnk4 pathway that
are leading to this phenotypic difference.
Through an unbiased proteomic screen, I identified a subset of upregulated
proteins in the KO cells that have the potential to be Cul3 substrates and possibly
be involved in FHHt, including ERK1, ERK2, STX4A, and GSN. After a careful
analysis, my results supported the hypothesis that ERK1 and ERK2 have the
potential to be Cul3 substrates and, in collaboration with WNK1 and WNK4, they
likely regulate the activity of the NCCs.
ERK1 and ERK2 are responsible for mediating cellular responses to injuries
and stress in the kidneys as well as the regulation of the NCCs. As mentioned in
chapter 3, upregulation of NCCs is the main cause of the increased blood pressure
and elevation of potassium levels observed in FHHt patients are triggered by
disruption of Cul3 and, as a result, enhanced activity of its substrates WNK1 and
WNK4. The fact that both WNKs and ERKs are kinases and control the activity of
NCCs in the DCT supports the hypothesis that the severe phenotype observed in
Cul3 knockouts is caused by simultaneous enhanced activity of multiple
substrates, and the ERKs are possibly part of this regulatory pathway.
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V.

Mechanisms of action and potential pathological consequences of
abnormal ERK signaling in FHHt

ERK1 and ERK2 are mitogen-activated protein kinases (MAPKs), which are
proteins responsible for initiating the activation of signaling pathways that act as
intracellular communication lines and contribute to structural and functional cellular
responses. They are mainly activated by stress stimuli, and are, therefore,
sometimes categorized as stress kinases (Kurtzeborn et al., 2019).
My hypothesis proposes that ERK1 and ERK2 are likely to be ubiquitinated
by Cul3 and targeted to degradation by the 26S proteasome. However, in Cul3 KO
cells, they can no longer be ubiquitinated, leading to a rise in their cellular levels
and, consequently, over-stimulating the kidney pathways in which they are
involved. As mentioned above, ERK1 and ERK2 mediate the activation of NCCs,
thus the over-expression of these two MAPKs likely enhances NCC activity, which
in turn contributes to the kidney tissue injury observed in severe cases of FHHt
(Figure 4.3).
To test my hypothesis that ERK1 and 2 are Cul3 substrates, I will have to
perform a series of biochemical tests, including (1) Examine if the levels of these
two MAPKs are higher in the Cul3 KO cells. This can be achieved by transfecting
them into WT and Cul3 KO cells and comparing their expression levels. (2) Test
their binding capability to the Cul3 complex through immunoprecipitation assays.
Then, I can take advantage of the Cul3 DBTB and compare the binding to the wild-
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type Cul3. (3) Through ubiquitination assays, determine if the ubiquitination levels
of ERK1 and ERK2 change in the presence and absence of Cul3.

MECHANISMS OF SUBSTRATE RECOGNITION BY CUL3
Cul3 selects protein substrates for the ubiquitination pathway by
recognizing a specific signal that is common only among its target proteins.
Several studies have mapped the BTB-binding regions on various Cul3 substrates.
However, such analyses have yet to reveal a consensus signal that initiates the
substrate selection process for Cul3. Although most substrates are targeted for
ubiquitination by a single cullin E3 ligase, emerging evidence demonstrates that a
few substrates can be ubiquitinated by several cullins. For instance, Maeda and
colleagues' in vitro ubiquitination assay revealed that both the Cul1 and Cul3 could
catalyze the polyubiquitination of cyclin D (Maeda et al., 2001). Even though it has
been well established that Cul3 catalyzes the ubiquitination and the subsequent
degradation of cyclin E in mice (Singer et al., 1999), a couple of studies have
shown that cyclin E is also a substrate of the SCFfbw7 complex (Koepp et al., 2001;
Strohmaier et al., 2001). Lastly, both Cul1 and Cul3 are responsible for the
ubiquitination of the Ci protein, which is a regulator of the hedgehog signaling
pathway involved in the development of the Drosophila eye (McEvoy et al., 2007;
Ou et al., 2002). In the following sections, I explore potential mechanisms of
substrate recognition and examine different cellular signaling events that may play
a role in the activation of the Cul3 complex and the recognition of its substrates.
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I.

Temporal regulation

The identification of substrates by cullins has focused primarily on the
interactions between their substrate adaptors and target proteins. An alternative
hypothesis for this model is that the ubiquitination pathway is under a temporal
regulation, and each cullin is only activated under specific cellular conditions. The
ubiquitination of the p53 protein is an interesting example of such regulation, in
which a single substrate is targeted for degradation by at least five different
ubiquitin ligases, including Mdm2, Cul7, ARF-BP1, COP1, and Pirh2 (Brooks and
Gu, 2006). Even though most of these ubiquitin ligases become functional by a
negative feedback loop that regulates the expression levels of p53, a few of them
are activated under specific cellular conditions. For example, Pirh2 targets p53 for
degradation in response to cellular damage (Duan et al., 2006), while Cul7
ubiquitinates p53 to promote cell growth (Andrews et al., 2006). Similarly, substrate
ubiquitination by Cul3 might be triggered by different cellular responses that have
not yet been characterized.

II.

Spatial regulation

The proximity of the target substrate with its ubiquitin ligase may lead to
substrate recognition and consequent activation of the ubiquitin ligase, which
would indicate that spatial regulation may play a role in the induction of the ubiquitin
ligase activity (Pines and Lindon, 2005). Therefore, it is possible that different cullin
ligases are not competing for the same substrate but rather coordinating their
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functions in separate cellular compartments or tissues based on their localization.
Ou and colleagues tested this hypothesis in a study about the development of the
Drosophila eye. They showed that both Cul1 and Cul3 are responsible for the
degradation of Ci during the third instar larva period (Ou et al., 2002). Although
Cul1 and Cul3 separately ubiquitinate Ci in the anterior and the posterior regions
to the morphogenic furrow, respectively, the expression of these cullins is not
limited to the region in which they are functionally active. For instance, Cul1 was
detected in the posterior of the morphogenic furrow where Cul3 alone targets the
ubiquitination of Ci, indicating that the presence of Cul1 in proximity to a potential
substrate does not activate its function as a ubiquitin ligase. Therefore, spatial
regulation does not necessarily influence either substrate selection or the
activation of cullin ubiquitin ligases. However, the possibility that substrate
selection is affected by the localization of cullin substrate adaptors or the ubiquitinconjugating enzymes (E2s) remains unknown.

III.

Binding based on specific types of protein-protein interactions:

A specific ubiquitin ligase might recognize different groups of substrates
differentiated by either post-translational modifications or complex formation with
other proteins. For instance, it has been determined that the SCFfbw7 complex
specifically binds cyclin E that has been phosphorylated at the Thr380 residue
(Koepp et al., 2001). Still, another study suggested that Cul3 is more likely to
recognize the non-phosphorylated form of cyclin E (Singer et al., 1999).
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Additionally, during the development of the Drosophila eye, phosphorylation by
protein kinase A (PKA) is essential for the Cul1-mediated degradation of the Ci
protein, as shown by the reduction of Ci expression in the presence of a
constitutively active PKA. However, the ability of Cul3 to ubiquitinate Ci substrates
is entirely independent of PKA activity, which further supports the hypothesis that
Cul1 and Cul3 mediate the ubiquitination of different subtypes of the same target
protein. Even though phosphorylation provides a recognition signal for Cul1
substrates, a substrate recognition factor for the Cul3-based ubiquitin ligase has
not yet been confirmed. By analyzing the interaction between Cul3 and the proteins
listed in Table 3.6, which is about the common domains found in the altered
proteins of our MS-based proteomic analysis, we may acquire valuable information
regarding the molecular basis of substrate recognition by the Cul3-based E3 ligase
complex.

IV.

Coordinated activity of different cullins and mechanisms of
compensation
It is also crucial to consider that multiple ubiquitin ligases targeting the same

substrate may confer a coping mechanism for cells and organisms. By allowing
the substitution of one ubiquitin ligase enzyme for another, an organism may
compensate for other mutations in the ubiquitination machinery. For instance, the
cell cycle regulator cyclin E is a well-characterized Cul3 substrate (Davidge et al.,
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2019), but studies have shown that both Cul1 and Cul3 are involved in its
degradation (Clurman et al. 1996; Singer et al. 1999; Petroski and Deshaies 2005).

CONCLUSIONS
Cul3-based E3 ligase is responsible for regulating a variety of cellular
pathways, many of which are known to have profound effects on the proper
function of multicellular organisms. Thus, we began this journey trying to elucidate
the physiological context in which this E3 ligase operates in mammalian cells, in
which we expected to identify relevant E2 partners, understand the role of BTB
domain-containing proteins in the recruitment of E2s, identify potential Cul3
substrates, and get a better understanding of their biological functions.
First, I have discovered that BTB adapter proteins are probably involved in
the E2 recruitment. Secondly, I proposed that the WD40/LRR domain-containing
proteins are likely to be substrate adaptors for the Cul3 complex, not substrates.
Third, the severe phenotype of Cul3 knockouts observed in FHHt, is likely to be
caused by the over-expression of multiple factors, including the two potential Cul3
substrates, ERK1 and ERK2, identified in my proteomics screen. Lastly, identifying
potential members of the Cul3 complex using the MS-based proteomic approach
has established a correlation between Cul3 and the over-activation of the NCC
pathway observed in FHHt. I hope that the knowledge gained from this dissertation
will be applied to achieve the ultimate goal that is to fully characterize the
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ubiquitination mechanism of the Cul3-based E3 ligase at the cellular and
organismal levels.
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Figure 4.1 – Models of E2 recruitment and substrate ubiquitination: (A) Current suggested
model of E2 recruitment and assembly with the Cul3 complex. (B) Proposed model of E2
recruitment and assembly with Cul3.
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Figure 4.3 - Schematic summary of the ERK1 and ER2 pathway: The ligand (pink triangle) binds
to the dimeric transmembrane tyrosine kinase receptor (blue/salmon blocks) and activates a
spectrum of downstream intracellular cascade. The MAPK pathway is highlighted in the light gray
box and mediates extracellular information to the cell interior. The last step of ERK cascade
activation results in phosphorylation of ERK1/2 leading to activation of the NCCs. In Cul3 knockout
cells, ERKs cannot be ubiquitinated by Cul3 and degraded by the 26S proteasome. Consequently,
ERK1/2 levels rise and overactivation of NCC happens.
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Table 4.1 - Substrates of CUL3-mediated non-proteolytic ubiquitylation.
Protein

Type of Ubiquitination

Aurora kinase B

Mono

H2AFY

Mono

Sec31

Poly (K33)

MCM3

Poly (K48)

Function
Regulation of mitotic localization
and chromosome segregation
Stable X chromosome inactivation
Assembly of large COPII coated
vesicles and collagen secretion
Loading and regulation of DNA
replication
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